ronald p. kaufman, jr., md, facs

Transcription

RONALD P. KAUFMAN, JR., M.D., F.A.C.S.
Associate Professor of Surgery
Assistant Professor of Physiology & Cell Biology
Associate Urology Residency Program Director
Albany Medical College
Urological Institute of Northeastern New York
Albany, New York
Office Address:
23 Hackett Blvd.
Albany, New York 12208
(518) 262-3341
EDUCATION:
1979
Bachelor of Science
Trinity College
Hartford, Connecticut
1983
Doctor of Medicine
The George Washington University School of
Medicine and Health Sciences
Washington, D.C.
POSTGRADUATE TRAINING:
1983 - 1984
Intern, General Surgery
Case Western ReserveIntegrated Hospitals of Cleveland
Cleveland, Ohio
1984 - 1986
Research Fellowship
The Harvard Medical SchoolBrigham and Women's Hospital
Boston, Massachusetts
1986 - 1987
Resident, General Surgery
Case Western ReserveIntegrated Hospitals of Cleveland
Cleveland, Ohio
1987 - 1991
Resident, Urologic Surgery
Duke University Medical Center
Durham, North Carolina
HONORS:
2004-2005
1996
1990
1981
1976
1976
1975
1973
CERTIFICATION:
AUA ID
1984
1984, 1988
1985
1991
1991
1993
1993
1994
1995
1995
1996
1997
1997
2000
2001
2005
2005
10/25/10
AUA Leadership Program Inaugural Class
(Northeastern Section, AUA Representative)
Pfizer Scholars in Urology Award
Finalist, The Montage L. Boyd Prize Essay Contest
Southeastern Section AUA
The William Beaumont Medical Society
Robert Slaughter Award in Swimming
Varsity Letter in Swimming
State of Connecticut Scholar
Eagle Scout
National Board of Medical Examiners
Advanced Cardiac Life Support
Advanced Trauma Life Support
E.S.W.L.
Laparoscopic Surgery
Diplomat of the American Board of Urology
Contigen Implant Training Program
Genitourinary Laser Certification
Prostate Cryosurgery
Vaportrode Prostatectomy
Transurethral Needle Ablation (TUNA)
3-D Ultrasound Guided Transperineal Brachytherapy for
Prostate Cancer
Holmium Laser Prostatectomy and Lithotripsy.
Hand Assisted Laparoscopic Renal Surgery
Re-Certified Diplomat of the American Board of Urology,
Robotic Laparoscopic Radical Prostatectomy
KTP/Green Light Laser Prostatectomy
Re-Certified Diplomat of the American Board of Urology,
LICENSURE:
1984
1988
1991
1993
Massachusetts
North Carolina
New York State
DEA
PROFESSIONAL SOCIETIES AND ORGANIZATIONS:
American Medical Association
District of Columbia Medical Society
Cleveland Academy of Medicine
Ohio State Medical Association
Massachusetts Medical Society
Medical Society of the State of New York
Medical Society of the County of Albany
American Urological Association
Eastern Cooperative Oncology Group
American Association of Clinical Urologists
2
Northeastern Section American Urologic Association
Society of University Urologists
PROFESSIONAL SOCIETIES AND ORGANIZATIONS:
Fellow American College of Surgeons
Society of Brigham Surgical Alumni
DYSURIA
Society of Urologic Oncology
Society of Laparoendoscopic Surgeons (SLS)
New York State Urological Society
ACADEMIC APPOINTMENTS:
1991 – 3/31/98
Assistant Professor of Surgery
Division of Urological Surgery
Albany, New York
4/1/98 – present
Division of Urologic Surgery
Albany, New York
1994 - present
Assistant Professor of Physiology
and Cell Biology
Department of Physiology
Albany, New York
1997 – present
Adjunct Clinical Associate Professor
University of Guadalajara
Guadalajara, New Mexico
PROFESSIONAL EXPERIENCE:
1991 - 5/1/98
Assistant Professor of Surgery
Albany, New York
1991 - 6/30/93
Staff Urologist
Samuel Stratton VA Medical Center
Albany, New York
1991 - present
ETNEP Advisory Board (Enterostomal Therapy Nurse
Education Program)
Albany, New York
1992 - present
Affiliate Staff
Department of Surgery, Division of Urology
Albany Memorial Hospital
600 Northern Blvd.
3
Albany, New York 12204
1992 - present
Reviewer, The Journal of Urology
Investigative Urology
1992 - present
Faculty
Prostate Ultrasound Course
Albany, New York
1992 - 6/30/93
Surgical Representative
Peer Review Committee
Albany, New York
1993 - present
Course Director, Contemporary Topics in Urology: 1993
June 10, 1993
1993 - present
Affiliate Staff
Albany, New York
7/93 - Present
Principal Investigator
"Albany Medical Center Annual Prostate Cancer Screening
Program"
7/1/93 - 8/15/94
Acting Head
Albany, New York
7/1/93 - 8/15/94
Acting Program Director
Albany, New York
7/1/93 - 7/1/95
OR Operations Committee
Albany Medical Center Hospital
Albany, New York
7/1/93 - 7/1/95
Operating Room Committee
Albany, New York
7/1/93 - 4/30/96
Department of Surgery Quality Management Committee
Albany, New York
11/8/93 - present
Bard Contigen Collagen Implant Preceptor
Albany, New York
4/1/94 - present
Assistant Professor of Physiology and Cell Biology
Department of Physiology
4
Albany, New York
7/1/94 - present
Cancer Committee
Albany, New York
4/1/95 - present
Medical Staff
Century Same Day Surgery
7 Century Hill Drive
Latham, NY 12110
11/15/95 - Present
Medical Staff
Department of Surgery (Urology)
St. Peter's Hospital
315 S. Manning Blvd.
Albany, NY 12208
12/1/95 - Present
Chairman
Department of Urology
Century Same Day Surgery
7 Century Hill Drive
Latham, NY 12110
3/12/96 - Present
Principal Investigator
"A Randomized Double Blind Comparative Trial of
Bicalutamide (Casodex) vs. Placebo in Patients with Early
Prostate Cancer"
5/15/96 - Present
Surgical In-Patient Improvement Team
7/96 - Present
Associate Urology Residency Program Director
9/1/96 - Present
OR Operations Committee
Albany, NY
9/1/96 - Present
Operating Room Committee
Albany, NY
10/12/96
Moderator BPH and Other Urologic Disorders: A Primary
Care Perspective
Desmond Hotel, Albany, NY
5
10/96 - Present
Consultant, Nycomed, Inc. Research & Development,
NC67722 Lymphography Agent Studies
3/97 - Present
Medical staff, Child's Hospital, 25 Hackett Blvd., Albany, NY
1997 - Present
Reviewer Southern Medical Journal
1998
Abstract Reviewer, 1998 American Urological Association
National Meeting Abstracts (Prostate Cancer-Advanced).
2/98 - Present
Urology Sub-Committee Capital District Physician's Health
Plan (CDPHP).
3/98
Sub-Investigator, “Phase III, Open Label, Randomized,
Parallel Active Control Study to Evaluate Efficacy and Safety
of Histrelin Subdermal Implant in Patients with Locally
Advanced Prostate Cancer.”
4/1/98 - Present
Principle Investigator, "No. R-0529 A Study to Evaluate the
Impact of Viagra on Treatment Satisfaction".
4/1/98 - Present
Division of Urology
Albany, New York
2/9/99-2/12/99
Faculty, 15th Annual Clinical Update in Obstetrics and
Gynecology, Stratton Mountain Inn, Stratton Mountain,
Vermont.
1999
National Meeting Abstracts (Prostate Cancer-Advanced).
10/28/98-Present
Principle Investigator, “A Randomized Double Blind
Comparative Trial of Bicalutamide (CASODEX) 150 mg.
versus Placebo Each in Combination with Castration as
Second-Line Therapy for Patients with Asymptomatic
Metastatic Prostate Cancer”.
10/98
Sub-Investigator, “A Phase III, Multi-Center, Open-Label,
Randomized Study of Abarelix-Depot vs. Lupron DepotÒ 1month plus Daily CasodexÒ In Patients with Prostate
Cancer Who are Candidates for Initial Hormonal Therapy.
1998-1999
Judicial Committee Northeastern Section of the American
Urological Association
1999
Course Director, Erectile Dysfunction and Benign Prostatic
Hyperplasia (BPH): Current Diagnosis and Management,
April 10, 1999.
8/99-Present
Principle Investigator, “A Double-Blind, Randomized, FixedDose, Placebo Controlled Study to Assess the Efficacy and
Safety of Sildenafil in Preventing Erectile Dysfunction in
6
Patients who have Undergone a Bilateral Nerve Sparing
Radical Prostatectomy”.
1999
Faculty, Update on Pediatric Urology and Prostate Cancer,
The Desmond Hotel, Albany, New York, September 25,
1999.
1999
Faculty, Clinical Directors Conference, Health Services
Division of the Federal Bureau of Prisons, San Diego,
California, December 7, 1999.
1999-Present
Reviewer, Urology
3/99
Sub-Investigator, “Phase III, Randomized, Double-Blind
Study of DFMO vs. Placebo in Low Grade Superficial
Bladder Cancer.”
6/5/99
Sub-Investigator, “A Phase III at Home Use Study
Evaluating the Efficacy and Safety of Escalating Doses of
Uprima 2, 3, and 4 mg in the Treatment of Patients with
Erectile Dysfunction.”
7/99-Present
Medicare Relative Value Scale Advisory Committee, Health
Policy Council Component Committee, American Urological
Association
9/99
Sub-Investigator, “A Phase III,Multi-Center, Open Label,
Randomized Study of Abarelix Depot IM vs. Lupron Depot
7.5mg in Patients with Prostate Cancer who are Candidates
for Initial Hormonal Therapy.
10/99
Sub-Investigator, “A Multi-Center Study of Abarelix Depot in
Patients with Prostate Cancer in Whom GnRH Agonists are
Contraindicated.”
10/99
Sub-Investigator, “A Rollover, Multi-Center, Open-Label,
Maintenance Study of Patients with Prostate Cancer who
were Previously Treated with Abarelix-Depot 50mg or
100mg IM.”
12/99
Sub-Investigator, “A Phase III, Six-Month, Long-Term,
Open-Label, Flexible Dose, Safety Extension of Uprima
Tablets (2, 3 and 4mg) in the Treatment of Male Erectile
Dysfunction.”
12/99
Sub-Investigator, “A National Phase III Trial of Intron,
Interferon-alpha 2b Plus BCG for Treatment of Superficial
Bladder Cancer.”
1999
Sub-Investigator, “A Randomized Prospective Study
Comparing Radical Prostatectomy Alone Versus Radical
Prostatectomy Preceded by Androgen Blockade in Clinical
B2 (Tb2NxMo) Prostate Cancer.”
1999-2000
Prize Essay Committee
Component of Program Committee, American Urological
7
Association
1999-2000
Ad Hoc Young Urologists Committee, American Urological
Association
1999-2000
Judicial Committee Northeastern Section of the American
Urological Assoc.
4/00
Sub-Investigator, “Phase IIb / III chemoprevention Trial of
Celecoxib to Prevent Recurrence of Superficial Bladder
Cancer.”
2000
Update 2000,
Course director, Male and Female Sexual Dysfunction
2000
Annual Meeting Scientific Program (Prostate CancerAdvanced).
2000-2001
Prize Essay Committee, Component of Program
Committee, American Urological Association.
2000-2001
Young Urologists Committee, American Urological
Association.
2001
Annual Meeting Scientific Program (Prostate CancerAdvanced).
2001-Present
Principle Investigator, Lupron Depot A-43818 Protocol
#M97-786 Randomized Prospective Study of Adjuvant
Androgen Ablation in Radical Prostatectomy Patients at
High Risk for Disease Recurrence.
2001-Present
Principle Investigator, AMS 002.1 Evaluation of the Safety
and Tolerability of Transurethral Dehydrated Alcohol
Injection for the Treatment of Benign Prostatic Hyperplasia.
April 2001
Sub-Investigator, A Two Phase, Double-Blinded,
Randomized, Parallel-Group Design, Multicenter Study of
Flomax Capsules, 0.4mg versus Placebo in Male Patients
with Acute Urinary Retention Related to Benign Prostatic
Hyperplasia.
May 18, 2001
Faculty: Recent Advances in Prostate Cancer, The
Fairmont Copley Plaza, Boston, Massachusetts.
June 2001
Sub-Investigator, A Phase III Randomized Double Blind
Placebo Controlled Study of the Safety and Efficacy of
10mg of Atresentan in Men with Metastatic Hormone
Refractory Prostate Cancer.
June 2001
Sub-Investigator, A Phase III Randomized Double Blind
Placebo Controlled Study of the Safety and Efficacy of
10mg of Atresentan in Men with Non-Metastatic Hormone
8
July 13, 2001
Faculty: Recent Advances in Prostate Cancer, The RitzCarlton, Atlanta, Georgia.
October 19, 2001
Moderator, Urologic Case Presentations Conference,
Champlain Valley Physicians Hospital Medical Center,
Plattsburgh, NY.
November 8, 2001
Visiting Professor, Department of Urology at SUNY Upstate
Medical University, Syracuse, New York
2001-2002
Association
2001-2002
Prize Essay Committee, Component of Program
Committee, American Urological Association
2002-2003
Association.
2002
Meeting Scientific Program (Prostate Cancer-Advanced).
January 23, 2002
Faculty: Hand Assisted Laparoscopic Renal Surgery,
Hartford Hospital, Hartford, Connecticut.
February 2002
Principle Investigator, “Evaluation of the Safety and
Tolerability of Transurethral Dehydrated Alcohol Injection for
the Treatment of Benign Prostatic Hyperplasia.”
February 2002
Sub-Investigator, Phase IIb, Multi-Center, Randomized,
Double Blind, Placebo Controlled Trial to Assess the Safety
and Efficacy of MPC-7869 in Delaying the Systemic
Progression of Prostate Cancer in Patients with Intermediate
to High Risk of Recurrence with Rising Prostate Specific
Antigen (PSA) Levels after Prostatectomy, Prostatectomy
and Radiotherapy, or Radiotherapy Alone for Localized
Disease.
April 5, 2002
Faculty: Recent Advances in the Management of Prostate
Cancer, The Ritz Carlton, Cleveland, Ohio.
April 19, 2002
Cancer, The Park Hyatt, Philadelphia, Pennsylvania.
May 10, 2002
Cancer, The Adam’s Mark Hotel, Charlotte, North Carolina.
July 19, 2002
Cancer, The Ritz Carlton Hotel, Dearborn, Michigan.
8/02-Present
Minimally Invasive Steering Council (MISC), Albany Medical
Center Hospital, Albany, New York.
April 2, 2002
Sub-Investigator, An Open-Label Study to Evaluate the
Feasibility of Switching to Treatment with an LHRH Agonist
9
Following 12 Weeks Treatment with Abarelix in Patients with
Prostate Cancer.
April 2002
Sub-Investigator, An Open-Label, Multi-Center, Ascending,
Single Dose Study Investigating the Pharmacokinetics,
Pharmacodynamics and Safety of FE200486 in Prostate
Cancer Patients.
August 16-18,2002
Faculty: Current Concepts in Men’s Health, The Sagamore
Resort, Lake George, Bolton Landing, New York.
September 2002Present
Faculty: Medical Knowledge Forums in Urology.
September 2002
Sub-Investigator, An Open Label Study to Evaluate the
Feasibility of Switching to Treatment with an LHRH Agonist
Following 4 Weeks of Treatment with Abarelix in Patients with
Prostate Cancer.
September 20, 2002 Faculty: Recent Advances in the Management of Prostate
Cancer, The New York Roosevelt Hotel, New York, New
York.
November 2002-
Health Policy Committee, Northeastern Section of The
American Urological
Association
Expert Medical Consultant for the Office of Professional
Medical Conduct.
Present
2003-2004
Association.
2003
2003
Highlight Presenter, Benign Prostatic Hyperplasia, 2003
American Urological Association Annual Meeting Plenary
Session, Chicago, Illinois.
February1-2, 2003
Sugar Loaf, USA.
Faculty: Maine Urological Association Winter Meeting 2003,
January 2003Applied Medical
Present
Preceptor: Hand Assisted Laparoscopic Renal Surgery,
April 2003
Sub-Investigator, An Open-Label, Multi-Center, Extension
Study Investigating the Long-Term Safety and Tolerability of
FE200486 in Prostate Cancer Patients.
May 31, 2003
Symposium,
Faculty: Male Sexual Health: Practical Clinical Solutions CME
Renaissance Dallas North, Dallas, Texas.
10
June 20, 2003
Cancer, The Ritz Carlton Dearborn, Dearborn, Michigan.
June 2003
Sub-Investigator, A Phase III Extension Study to Evaluate the
Safety of 10mg of Atresentan in Men with Hormone
August 1, 2003
Cancer, The Four Seasons Hotel, Washington, DC.
August 15-17, 2003
Faculty: Current Concepts in Men’s Health, The Sagamore
Resort, Lake George, Bolton Landing, New York.
August 2003
Principle Investigator, An Open Label Study to Evaluate the
Efficacy and Safety of Tadalafil Administered “On Demand”
to Men of Various Populations with Erectile Dysfunction.
November 12, 2003
Moderator: Advances in the Treatment Strategies for
Prostate Cancer, The Desmond Hotel and Conference
Center, Albany, New York.
November 2003Present
Member: Executive Committee New York State Urological
Society
2003
Abstract Reviewer: 2004 American Urological Association
January 17, 2004
Moderator: Sexual Health Hospital Symposia Half Day CME
Program, The Desmond Hotel and Conference Center,
Albany, New York.
January 17, 2004
Faculty: Sexual Health Hospital Symposia Half Day CME
Program, The Desmond Hotel and Conference Center,
Albany, New York.
January 2004
Principal Investigator, A Double Blind, Randomized, Placebo
Controlled Multicenter Study to Evaluate the Effects of
Rofecoxib in Decreasing the Risk of Prostate Cancer (Vioxx
Prostate Cancer VIP Study).
January 2004
Sub-Investigator, Study of Duloxetine HCL in Women of
Different Demographic Characteristics and Co-morbidities
with Stress Urinary Incontinence: Evaluation of Efficacy and
Safety.
January 2004
Principal Investigator, An Open Label, Randomized, MultiCenter, Parallel Group Comparison of the Efficacy and
Safety of Degarelix at Two Different Dosing Regimens in
Patients with Prostate Cancer for Thirteen 28 Day Cycles.
January 2004
Principal Investigator, A Randomized, Double Blind Placebo
Controlled Parallel Group Study of the Efficacy and Safety of
Dutasteride 0.5mg Administered Once Daily for Four Years
to Reduce the Risk of Biopsy-Detectable Prostate Cancer.
11
January 2004
Sub-Investigator, A Randomized, Double-Blind, Placebo
Controlled Phase 3 Trial of Immunotherapy with Autologous
Antigen Presenting Cells Loaded with PA2024 (Provenge
APC 8015) in Asymptomatic Subjects with Gleason Sum =7,
Metastatic, Androgen Independent Prostatic
Adenocarcinomas.
January 2004
Sub-Investigator, An Open Label Single Arm Trial of
Immunotherapy with Autologous Antigen Presenting Cells
Loaded with PA2024 (APC8015F) for Subjects with Objective
Disease Progression and Disease Related Pain on Protocol
D9902 Part B.
January 2004
Principal Investigator, The Effect of Zometa Compared to
Placebo on Bone Mineral Density in Patients Undergoing
Androgen Deprivation Therapy.
January 2004
Principal Investigator, REALISE, Real Life Safety and
Efficacy A Post Marketing Surveillance Study of Levitra
April 2004
Cancer, The Ritz Carlton Chicago, Chicago, Illinois, April 2,
2004.
April 2004
Cancer, W Atlanta Hotel, Atlanta, GA, April 16, 2004.
May 2004
Moderator: Poster Session #29, BPH: Epidemiology, Natural
History/Evaluation And Surgical Therapy and New
Technology, 2004 American Urological Association Annual
Meeting, San Francisco, California, May 11, 2004.
June 2004
Principal Investigator, Prospective Observational Registry
and Patient Survey of the Management of Men with
Symptomatic Benign Prostatic Hyperplasia (BPH), BPH
Registry and Patient Registry.
June 2004
Sub InvestigatorA Randomized, Double-Blind, PlaceboControlled,
Parallel Group Evaluation of the
Efficacy and Tolerability of Two Different Doses of
ELMIRON for the Treatment of Interstitial Cystitis. Protocol
# C-2002-036-02
June 2004
Sub-Investigator, A Phase III, Parallel Group, Randomized,
Double-Blind, Placebo Controlled, Multi-center Trial to
Investigate the Efficacy and Safety of Sustained Release
Fesoterodine in Subjects with Overactive Bladder
Syndrome.
July 2004
Sub-Investigator, A Randomized, Double-Blind, PlaceboControlled, Multicenter Efficacy and Safety Study of
Toremifene Citrate for the Prevention of Bone Fractures in
Men with Prostate Cancer on Androgen Deprivation
Therapy.
July 2004
Sub-Investigator, A Randomized, Double-blind, PlaceboControlled Study to Evaluate AMG 162 in the Treatment of
12
Bone Loss in Subjects Undergoing Androgen Deprivation
Therapy for Non-Metastatic Prostate Cancer.
July 2004
Sub-Investigator, Long Term Open Label Extension Trial for
Subjects Completing the Phase III Trial of Fesoterodine
(SP5584) for the Treatment of OAB Syndrome, Protocol
SP739.
July 2004
Principal Investigator, Prospective, Observational Registry
of the Management of Men with Prostate Cancer and a
Rising PSA Following Definitive Surgical or Radiological
Treatment of the Primary Tumor: PCA Registry COMPARE
) Comprehensive, Observational, Multicenter Prostate
Adenocarcinoma Registry.
July 2004
Sub-Investigator, A Phase II, Randomized, Double-blind,
Placebo-controlled, Study to Evaluate the Safety and
Efficacy of Prostavac-VF/TRICOM in Combination with
GMCSF in Patients with Androgen-Independent
Adenocarcinoma of the Prostate.
May 2004
Sub Investigator: A Randomized, Double-Blind, PlaceboControlled, Multicenter Efficacy and Safety Study of
Toremifene Citrate for the Prevention of Bone Fractures in
Men with Prostate Cancer on Androgen Deprivation
Therapy. Protocol G300203
July 9, 2004
Cancer, The Pierre, New York, New York.
August 2004
Faculty: Current Concepts in Men’s Health 2004, The
Sagamore Resort Lake George, Bolton Landing, New York,
August 13-15, 2004.
October 2004
Moderator: Renal Cell Carcinoma/Genetics, The
Northeastern Section of the American Urological
Association Meeting, Westin Savannah Harbor Resort,
Savannah, Georgia, October 29, 2004.
October 2004
Moderator: Poster Session, The Northeastern Section of
the American Urological Association Meeting, Westin
Savannah Harbor Resort, Savannah, Georgia, October, 29,
2004.
November 2004
Principal Investigator: Protocol # A6061023, A Phase 2,8
week Multi-Center, Randomized double-Blind, Placebo
Controlled, Parallel Group Study Evaluating the Efficacy,
Tolerability and Safety od (S,S) - Reboxetine (PNU165442G) For Stress Urinary Incontinence in Women
January 2005
Principal Investigator: Clinical Study BO18040, titled
"Randomized, two arm, placebo controlled study to
compare the efficacy of intravenous loading doses followed
by maintenance treatment with intravenous ibandronic acid
versus zoledronic acid in patients with skeletal metastases
13
experiencing moderate to severe pain.”
January 2005
Sub Investigator: Protocol: R096769-PRE-3002A PlaceboControlled, Double- Blind, Randomized, Parallel Study of the
Withdrawl Effects of Chronic Daily and as Needed Dosing
with Dapoxetine in the Treatment of Premature Ejaculation
February 2005
Faculty: Men’s Health for the Primary Care Provider: Skills
You Can Use, The Desmond Hotel, Albany, New York,
February 12, 2005.
April 2005
Faculty: 2005 Prostate Cancer Update, InterContinental
Hotel, San Juan, Puerto Rico, April 9, 2005.
May 2005
Moderator: Podium Session #08, Sexual
Function/Dysfunction/Andrology: Medical and Non-Surgical
Therapy(1), American Urological Association Annual
Meeting , San Antonio, Texas, May 23, 2005.
July 2005
Cancer, Grand Hyatt New York, New York, New York, July
29, 2005.
July 2005
Sub-Investigator: A Randomized, Double-Blind, PlaceboControlled, Multicenter Efficacy and Safety Study of
Toremifene Citrate for the Prevention of Prostate Cancer in
Men with High Grade Prostatic Intraepithelial Neoplasia
(PIN)
Protocol # G300104
August 2005
Sagamore Resort, Lake George, Bolton Landing, New York,
August 12-14, 2005.
August 2005
Sub-Investigator, A multicenter, multiphase, single arm,
open label study to evaluate the effects of tolterodine ER in
conjunction with behavioral intervention on subject
satisfaction and overactive bladder symptoms (urgency
urinacy incontinence (UUI), urgency, frequency) in
overactive bladder subjects who were dissatisfied with their
most recent antimuscarinic OAB medication therapy.
Protocol # A6121146
September 2005
Principal Investigator: A Multi-Center, Randomized Phase 3
Study of Adjuvant Oncophage® Versus Observation in
Patients With High Risk of Recurrence After Surgical
Treatment for Renal Cell Carcinoma. Protocol # C-100-12
AUA Coding and Reimbursement Committee
September 2005September 2006
AUA Practice Management Adhoc Committee
2005 - present
Abstract Reviewer: 2006 American Urological Association
14
Meeting Scientific Program (General & Epidemiological
Trends: Outcomes, Practice Patterns, Quality of Life, Cost
Effectiveness).
December 2005
Sub-Investigator Amgen Protocol 20050147 A Randomized
,Double-Blind, Placebo-Controlled, Multi-Center Phase 3
Study of Denosumab on Prolonging Bone Metastasis-Free
Survival in Men with Hormone-Refractory Prostate Cancer.
2005-Present
Reviewer, Journal of Urology
2006-Present
Reviewer, Urologic Oncology: Seminars and Origional
Investigations
May 2006
Moderator: Discussed Poster Session # DP13 Prostate
Cancer: Localized (ll), American Urological Association
Annual Meeting, Atlanta, GA, May 23, 2006.
May 2006
Program Committee, Northeastern Section of the AUA,
Ottawa program.
July 2006
Faculty: 2006 Prostate Cancer Review: Redefining Disease
Management, The Westin Southfield Detroit, Southfield,
Michigan, July 28, 2006.
July 2006
Principal Investigator: A randomized, Double-blind, PlaceboControlled Trial Assessing the Efficacy and Safety of
dutasteride in Extending the Time to Progression of LowRisk, Localized Prostate Cancer in men who are Candidates
for Undergoing Expectant Management
July 2006
Sub-Investigator: A randomized, double-blind, multi-center
study of Denosumab Compared with Zoledronic Acid
(Zometa ®) in the Treatment of Bone Metastases in Men with
Hormone-Refractory Prostate Cancer AMG 20050103
July 2006
Principal Investigator: A Randomized, Double-blind, phase III
study to evaluate adjuvant cG250 treatment versus placebo
in patients with clear cell RCC and high risk of recurrence
WX-2003-07HR
August 2006
Sub-Investigator: A phase II randomized, multicenter, placebo
controlled double-blind, dose-ranging clinical trial to study the
efficacy and safety of 5,15 or 25mg/day of CyPat ™
(Cyproterone Acetate) for the treatment of Hot Flashes
Following Surgical or Medical Castration of Prostate Cancer
Patients
August 2006
Faculty:Current Concepts in Men’s Health 2006, The
August 11 – August 13, 2006.
September 2006September 2007
Chair, Program Committee Northeastern Section AUA A
Annual Meeting, Rochester, NY September 12 – 17, 2007
September 9, 2006
Moderator: Moderated Poster Session IV-Other Cancer,The
15
Northeastern Section of the American Urological Association
Meeting, Ottawa, Canada
September 21-2006
Sub-Investigator: A Randomized Double-blind, Placebocontrolled Multi-center Efficacy and Safety Extension Study
of Toremifene Citrate for the Prevention of Bone Fractures
in Men with Prostate Cancer on Androgen Deprivation
Therapy. Protocol G300204
2006 – 2007
Program Committee Northeastern Section AUA Annual
Meeting, Rochester, NY September 12 – 17, 2007
2006 - present
Health Policy Committee Northeastern Section AUA
April 9, 2007
Principal Investigator: A Randomized Double-Blind Parallel
Group Study Comparing Casodex 50mg plus Placebo to
Casodex 50mg plus dutasteride 3.5mg Administered for 18
months to Men with Prostate Cancer Who Have Failed FirstLine Androgen Deprivation Therapy (Assessed by Rising
PSA) Followed by a Two-Year Extension Phase AVO108943
REDEEM
May 4, 2007
Principal Investigator: Post Marketing Study Using Prolieve
TM
For The Treatment of Benign Prostatic Hyperplasia
(BPH)
May 2007
Moderator: Moderated Poster # 3, General & Epidemiological
Trends &
Socioeconomics: Outcomes, Practice
Patterns, Quality of Life, Cost
Effectiveness (1),
American Urological Association Annual Meeting, Anaheim,
CA, May19, 2007.
September 6, 2007
Moderator: State-of-the-Art Lectures 1-4 & 5-8, The
Northeastern Section of the American Urological Association
Meeting, Rochester, NY.
January 9, 2008
Sub-Investigator: Phase II Randomized Double Blind
Placebo-Controlled Study to Determine the Efficacy of
ABR-215050 in Asymptomatic Patients with Metastatic
Castrate-Resistant Prostate Cancer
March 10, 2008
Principal Investigator: A Phase III, Randomized, DoubleBlind, Parallel Group, Placebo Controlled, Multi-center Study
to Assess the Efficacy and Safety of the Beta-3 Agonist
YM178 in Subjects with Symptoms of Overactive Bladder.
178-CL-047 ARIES
March 11, 2008
Principal Investigator: A Phase 2, Randomized, DoubleBlind, Parallel Group, Placebo Controlled, Multi-Center
Study to Evaluate the Safety of the Co-administration of
Solifenacin Succinate with 0.4 mg Tamsulosin
Hydrochloride OCAS (TOCAS) Using Urodynamics in Male
Subjects with Lower Urinary Tract Symptoms (LUTS) and
Bladder Outlet Obstruction (BOO)”905-CL-058
April 22, 2008
Principal Investigator: A Randomized, Double-Blind, Parallel
16
Group, Active Controlled, Multi-center Long-term Study to
Assess the Safety and Efficacy of the Beta-3 Agonist
YM178 in Subjects with Symptoms of Over active Bladder.
178-CL-049 TAURUS
May 2008
May 2008 - present
Moderator: Podium Session #02, General & Epidemiological
Trends &
Socioeconomics: Outcomes, Practice
Patterns, Quality of Life and Cost
Effectiveness (1),
American Urological Association Annual Meeting, Orlando,
Florida, May 17, 2008.
Chairman, Coding & Reimbursement Committee, American
Urological Association.
May 2008 - present
Member, Health Policy Council, American Urological
Association
August 2008
August 8-10, 2008`
September 24 2008
Sub-Investigator: A Multicenter, Randomized, PlaceboControlled, Double-Blind, Phase 3 Trial of Single-Dose
Intravesical EOquin ® as a Surgical Adjuvant Instilled in the
Early Postoperative Period in Patients Undergoing
Transurethral Resection for Noninvasive Bladder Cancer.
November 2008 -
American Urological Association G. James Gallagher Health
Policy Scholar present Program Selection Committee
January 30, 2009
Sub Investigator: An Open Label, Single Arm, Extension
Study to Evaluate the Long Term Safety of Denosumab
(AMG 162) in the Treatment of Bone Loss in Subjects
Undergoing Androgen-Deprivation Therapy for Nonmetastatic Prostate Cancer
March 2009
Faculty: 41st Annual Duke Urologic Assembly, Four Seasons
Hotel, Las Vegas, Nevada, March 7-10, 2009
March 10 2009
Sub-Investigator: A Randomized, Open Label Multicenter,
Phase III, 2-Arm Study of Androgen deprivation with
leuprolide +/- docetaxel for Clinically Asymptomatic Prostate
Cancer Subjects with a rising PSA Following Definitive Local
Therapy
April 2009
Moderator: Podium Session # 9, General & Epidemiological
Trends & Socioeconomics: Outcomes, Practice Patterns,
Quality of Life and Cost Effectiveness (II), American
Urological Association Annual Meeting, Chicago, IL, April 26,
2009.
April 2009
Faculty: Coding and Reimbursement Update 2009 American
Urological Association Annual Meeting, Chicago, Illinois, April
27, 2009.
June 15 2009
Principal Investigator: Follow up Study for REDUCE Study
17
Pateints ARI103094
August 2009
October 2009 –
September 2010
October 2009present
October 2009 –
present
August 14 – August 16, 2009`
.
Secretary-Elect, Northeastern Section American Urological
Association
Section Secretaries/Membership Council, American
Northeastern Section American Urological Association Board
of Directors
September 2009
Sub-Investigator: Bladder Cancer Recurrence Surveillance
Trial PBS-001
October 2009
Sub-Investigator: Hematuria Evaluation Trial PBS002
December 10 2009
Principal Investigator: A Phase 2, Multicenter, Randomized,
Single-Blind Study of Vitespen (HSPPC-96, Oncophage ®)
for Immune Response Assessment Following Treatment of
Patients with Resectable Renal Cell Carcinoma at
Intermediate Risk of Recurrence C-100-38
March 2010
Faculty: 42nd Annual Duke Urologic Assembly, Disney’s
Grand Floridian Resort
Spa, Lake Buena Vista, Florida, March 25-28, 2010
March 2010
DYSURIA Visiting Professor, 42nd Annual Duke Urologic
Assembly, Disney’s Grand Floridian Resort & Spa, Lake
Buena Vista, Florida, March 25-28, 2010.
April 2009
Faculty: Coding and Reimbursement Update 2010
American Urological Association Annual Meeting, San
Francisco, CA May 2010
July 2010 –
present
AMA CPT Advisory Committee representing the American
July 2010-
Albany Medical Center Operative/Anesthesia Services QIT
Committee
September 2010-
Secretary, Northeastern Section American Urological
Association
May 2011- present
Bylaws Committee, American Urological Association
18
May 2011- present
Faculty: Coding and Reimbursement Update 2011
American Urological Association Annual Meeting,
Washington, D.C., May 2011,
August 2011
Sagamore, Lake George, Bolton Landing, New York,
August 12 – August 14, 2011`
October 2011
Moderator, Moderated Poster Session I: Oncology 1,
Northeastern Section of the American Urological
Association 63rd Annual Meeting, Roosevelt Hotel, New
Orleans, LA October 27, 2011
RESEARCH EXPERIENCE:
1984 - 1986
Research Fellowship, National Research Science Award
Herbert B. Hechtman, M.D., Department of Surgery
The Harvard Medical School/Brigham Women's Hospital
Boston, Massachusetts
Investigated prostanoid mediation of non-hydrostatic
pulmonary edema and prostanoids as modulators of the
local and systemic pathophysiology of ischemia.
1980
Medical Student Summer Fellow
Nicholas R. Hall, Ph.D., Department of Biochemistry
The George Washington University School of Medicine and
Health Sciences, Washington, D.C.
1980
Investigated thymic hormones as an important component in
the bidirectional flow of information between the CNS and the
immune system.
1978 - 1979
Research Assistant
John E. Simmons, Ph.D.
Trinity College
Investigated the ability of non-aromatizable androgens to
effect aggressive behavior in female mice.
1978
Summer Student Fellow
Martin Berman, M.D., Department of Pathology
Hartford Hospital
Investigated estrogen receptors in benign liver tumors.
PUBLICATIONS:
1.
Kaufman RP Jr., Kobzik L, Valeri CR, Shepro D, Hechtman HB. Vasodilator
prostaglandins (PG) prevent renal damage after ischemia. Surgical Forum 36:435436, 1985.
19
2.
Anner H, Kaufman RP Jr., Kobzik L, Valeri CR, Shepro D, Hechtman HB.
Pulmonary hypertension and leukosequestration with ischemia induced Tx
production. Surgical Forum 37:312-314, 1986.
3.
Austin JC, Berrizbeitia LD, Hein RA, Kaufman RP Jr., Disesa VJ, Shemin RJ,
Hechtman HB, Cohn LH. Thromboxane synthetase inhibition reduces ventricular
irritability after coronary occlusion and reperfusion. Surgical Forum 37:250-252,
1986.
4.
Kaufman RP Jr., Kobzik L, Valeri CR, Shepro D, Hechtman HB. Vasodilator
prostaglandins (PG) prevent renal damage after ischemia. Ann Surg 205(2):195198, 1987.
5.
Kaufman RP Jr., Anner H, Kobzik L, Valeri CR, Shepro D, Hechtman HB. High
plasma PG/Tx ratio protects against renal ischemia. Surg Gynec Obstet 165:404409, 1987.
6.
Pulmonary hypertension and leukosequestration after lower torso ischemia. Ann
Surg 206:642-648, 1987.
7.
Pulmonary leukosequestration induced by hind limb ischemia. Ann Surg 206(2):162167, 1987.
8.
Kaufman RP Jr., Klausner JM, Anner H, Feingold H, Kobzik L, Valeri CR, Shepro
D, Hechtman HB. Inhibition of thromboxane (Tx) synthesis by free radical
scavengers. J Trauma 28(4):458-464, 1988.
9.
Anner H, Kaufman RP Jr., Valeri CR, Shepro D, Hechtman HB. Reperfusion of
ischemic lower limbs increases pulmonary microvascular permeability. J Trauma
28(5):607-610, 1988.
10.
Austin JC, Berrizbeitia LD, Schoen FJ, Kaufman RP Jr, Hechtman HB, Cohen LH:
Thromboxane synthetase inhibition reduces ventricular irritability after coronary
occlusion and reperfusion. Am Heart J 115:505-509, 1988.
11.
Kaufman RP Jr, Keane TE, Tucker JA, Hechtman HB, Walther PJ: A
pharmacologically-induced increased plasma prostacyclin (PGI2) to thromboxane
(TxA2) ratio protects the testis from ischemic necrosis. Surgical Forum 41:713-715,
1990.
12.
Kaufman RP Jr, Carson CC: Operations for testicular torsion. In JW Fowler (ed),
Mastery of Surgery: Urologic Surgery, 1992, pp. 562-566.
13.
Kaufman RP Jr, Carson CC: Management of testicular trauma. In JW Fowler
(ed), Mastery of Surgery: Urologic Surgery, 1992, pp. 589-591.
14.
Kaufman RP Jr, McCandless BK, Malik AB: Neutrophil (PMN) CD18 Integrin
mediates endotoxin-induced intrarenal PMN Sequestration. Surgical Forum 43:732734, 1992.
15.
Reddy PP, Kaufman RP Jr., McCandless BK, Neumann PH, Malik AB: Thrombin
Induced Expression of Neutrophil (PMN) CD18 Integrin: A Mechanism for
Intrarenal PMN Sequestration. Surgical Forum 44:767-770, 1993.
20
16.
Kaufman RP Jr., Carson CC: Ureteroscopic Management of Transitional Cell
Carcinoma of the Ureter Using the Neodymium:YAG Laser. Lasers in Surgery and
Medicine 13:625-628, 1993.
17.
McCandless, BK, Kaufman RP Jr., Cooper, JA, Neumann, PH, Malik, AB.
Mediation of lung neutrophil uptake after endotoxin by CD18-integrin-dependent and
-independent mechanism. Am. J. Physiol. 266:H1451-H1456, 1994.
18.
Wu VH, Dangman BC, Kaufman RP Jr.: Sonographic appearance of acute
testicular venous infarction in a patient with a hypercoagulable state. J. Ultrasound
Med. 14:57-59, 1995.
19.
Kallakury BVS, Figge J, Leibovich B, Hwang J, Rifkin M, Kaufman RP Jr., Figge
HL, Nazeer T, Ross JS. Increased bcl-2 protein levels in prostatic
adenocarcinomas (PAC) are not associated with rearrangements in the 2.8 kb
major breakpoint region (MBR) or with P53 protein accumulation. Modern Pathology
9:1-6, 1996.
20.
Perrotti M, Gentle DL, Barada JH, Wilbur HJ, Kaufman RP Jr. Mini-laparotomy
pelvic lymph node dissection minimizes morbidity, hospitalization and cost of pelvic
lymph node dissection. J. Urol. 155:986-988, 1996.
21.
Gentle DL, Kaufman RP Jr., Mandell J: Use of the Nd:YAG laser for removal of a
congenital posterior urethral polyp in a three year old child: A case report and review
of the literature. Urology 47:445-447, 1996.
22.
Perrotti M, Kaufman RP Jr., Jennings TA, Thaler HT, Soloway MS, Rifkin MD and
Fisher HAG: Enco-Rectal Coil Magnetic Resonance Imaging in Clinically Localized
Prostate Cancer: Is it Accurate? J. Urol. 156:106-109, 1996.
23.
Kallakury BVS, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HAG,
Kaufman R, Figge H, Ross JS: Decreased levels of CD44 protein and mRNA in
prostate carcinoma correlation with tumor grade and ploidy. Cancer. 78:1461-9,
1996.
23.
Ross JS, Sheehan C, Hayner-Buchan A, Ambros RA, Kallakury BVS, Kaufman R,
Fisher HAG, Muraca PF: HER-2/neu gene amplification status in prostate cancer by
fluorescence in situ hybridization. Human Path. 28(7):827-833, 1996.
24.
Kallakury BVS, Figge J, Leibovich B, Hwang J, Rifkin M, Kaufman R, Figge HL,
Nazeer T, Ross JS. Increased bcl-2 protein levels in prostatic adenocarcinomas
are not associated with rearrangements in the 2.8 kb major breakthrough region or
with P53 protein accumulation. Modern Pathol 9(1):41-47, 1996.
25.
Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BVS, Kaufman
RP, Jr., Fisher HAG, Rifkin MD, Muraca PJ: Prognostic significance of HER-2/neu
gene amplification status by flourescence in situ hybridization of prostate
carcinoma. Cancer. 79:2162-2170, 1997.
26.
Kallakury BVS, Sheehan CE, Ambros RA, Fisher HAG, Kaufman RP Jr., Ross JS:
The prognostic significance of p34 CDC2 and Cyclin D1 protein expression in
prostate adenocarcinoma. Cancer. 80:753-63, 1997.
27.
White MD, Kaufman RP, Jr., Das AK, Fisher HAG, Mehlhaff BA: Transurethral
vaporization of the prostate: An efficacious and durable tretament for benign
21
prostatic hyperplasia. Surgical Forum. 48:625-628, 1997.
28.
Kallakury BVS, Brien TP, Lowry CV, Muraca PJ, Fisher HAG, Kaufman RP, Jr.,
Ross JS: Telomerase activity in human benign prostate tissue and prostatic
adenocarcinomas. Diagn. Mol. Pathol. 6 (4): 192-198, 1997.
29.
Groudine SB, Fisher HAG, Kaufman RP, Jr., Patel MK, Wilkins LJ, Mehta SA,
Lumb PD: Intravenous lidocaine speeds the return of bowel function, decreases
postoperative pain, and shortens hospital stay in patients undergoing radical
retropubic prostatectomy. Anesth. Analg. 86:235-9, 1998.
30.
Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr., Muraca PJ,
Ross JS: Correlation of p34cdc2 Cyclin-Dependent Kinase Over-Expression,
CD44s Down Regulation, and HER-2/neu Oncogene Amplification with Recurrence
in Prostatic Adenocarcinomas. J. Clin. Oncol. Vol. 16:1302-1309, 1998.
31.
White MD, Das AK, Kaufman RP, Jr.: Gangrenous cystitis in the elderly:
Pathogenesis and management options. British Journal of Urology 82:297-299,
1998.
32.
White MD, Das AK, Rivard DJ, Kaufman RP, Jr.: Outcome analysis of needle
cystourethropexy for female stress urinary incontinence. Journal of Pelvic Surgery
4:204-207, 1998.
33.
Ross JS, Sheehan CE, Ambros RA, Nazeer T, Jennings TA, Kaufman RP, Jr.,
Fisher HAG, Rifkin MD, Kallakury BVS: Needle biopsy DNA ploidy status predicts
grade shifting in prostate cancer. AMJ Surg. Pathol. 23(3):296-301, 1999.
34.
Wharton JM, Chhieng DC, Hou J, delRosario AD, Kaufman RP Jr., Ross JS:
Growth factor expression in clear cell renal cell carcinoma. Journal of Urologic
Pathology 9:103-113, 1998.
35.
Kallakury BVS, Sheehan CE, Rhee SJ, Fisher HAG, Kaufman RP Jr., Rifkin MD,
Ross JS: The prognostic significance of proliferation-associated nucleolar protein
p120 expression in prostate adenocarcinoma. Cancer 85:1569-1576, 1999.
36.
Block J, Kaufman RP Jr.: Sickle cell disease – urologic considerations. NL
Gomella (ed.), The 5-minute urology consult, 2000, pp 500-501.
37.
Abrahams HM, Graber MW, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman
RP Jr., Ross JS. Prognostic significance of topoisomerase lla overexpression in
transitional cell carcinoma of the urinary bladder. Journal of Urologic Pathology
13:13-22, 2000.
38.
Kallakury BVS, Sheehan CE, Winn-Dean E, Oliver J, Fisher HAG, Kaufman RP
Jr., Ross JS: Decreased Expression of Catenins (α and β), p120 CTN, and ECadherin Cell Adhesion Proteins and E-Cadherin Gene Promoter Methylation in
Prostatic Adenocarcinomas. Cancer 92:2786-95, 2001.
39.
Ross JS, Sheehan CE, Fisher HAG, Kaufman R, Dolen EM, Kallakury BVS.
Prognostic markers in prostate cancer. Expert Rev Mol Diag 2(2):89-102, 2002.
40.
Ross JS, Kaur P, Sheehan CE, Fisher HAG, Kaufman RP Jr., Kallakury BVS:
Prognostic Significance of Matrix Metalloproteinase 2 and Tissue Inhibitor of
Metalloproteinase #2 Expression in Prostate Cancer. Mod Path 16 (3):198-205,
2003.
22
41.
Ross JS, Jennings TA, Nazeer T, Sheehan CE, Fisher HAG, Kaufman RP, Anwar
S, Kallakury BVS. Prognostic Factors in Prostate Cancer. Am J Cllin Pathol
120:S85-S100;2003.
42.
Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray
GS, Mosher R, Kallakury BV. Correlation of primary tumor prostate-specific
membrane antigen expression with disease recurrence in prostate cancer. Clin
Cancer Res. 2003 Dec 15;9(17):6357-62.
43.
Kaur P, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman RP Jr., Ross JS.
Survivin and bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med.
128:39-43;2004.
44.
Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K,
Stringer B. Expression of Nuclear Factor-kappa B and l kappa B alpha Proteins in
Prostatic Adenocarcinomas: Correlation of Nuclear Factor-kappa B
Immunoreactivity with Disease Recurrence. Clin Cancer Res. 2004 Apr 1;
10(7):2466-72.
45.
Moore CK, Karikehalli S, Nazeer T, Fisher HA, Kaufman RP Jr, Mian BM.
Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical
small proliferation in the contemporary era.
J Urol. 2005 Jan;173(1):70-2.
46.
Capello SA, Kogan BA, Giorgi LJ Jr, Kaufman RP Jr. Prenatal ultrasound has led to
earlier detection and repair of ureteropelvic junction obstruction. J Urol. 2005
Oct;174(4 Pt 1):1425-8.
47.
Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS.
Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic
adenocarcinomas. Hum Pathol. 2005 Nov;36(11):1204-9.
48.
Mian BM, Lehr DJ, Moore CK, Fisher HA, Kaufman RP Jr, Ross JS, Jennings TA,
Nazeer T. Role of prostate biopsy schemes in accurate prediction of Gleason
scores. Urology; 2006 Feb;67(2):379-83.
49.
Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS.
Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with
prognostic variables in prostatic adenocarcinomas. Hum Pathol. 2007
Apr;38(4):564-9.
50.
Bratslavsky G, Fisher HA, Kaufman RP Jr, Voskoboynik D, Nazeer T, Mian BM.
PSA-related markers in the detection of prostate cancer and high-grade disease in
the contemporary era with extended biopsy. Urol Oncol. 2008 Mar-Apr;26(2): 16670.
51.
Badger WJ, De EJ, Kaufman RP Jr. Robotically assisted excision of ovarian vein
for intermittent ureteral obstruction. JSLS. 2008 Apr-Jun;12(2):166-8.
52.
Bauer R, Kaufman R, Mian BM. Use of anticholinergic therapy in men. Can J Urol.
2008 Dec; 15(6):4359-62.
53.
Firoozi F, Nazeer T, Fisher HA, Kaufman RP Jr, White MD, Mian BM. Tissuemarking scheme for a cost-effective extended prostate biopsy protocol. Urol Oncol.
2009 Jan-Feb;27(1): 21-5.
23
ABSTRACTS:
1.
Kaufman RP Jr., Anner H, Kobzik L, Valeri CR, Shepro D, Hechtman HB.
Protection against renal ischemia by increasing plasma PG/Tx. Federation
proceedings 45:4695, 1986.
2.
Kaufman RP Jr., Anner H, Feingold H, Valeri CR, Shepro D, Hechtman HB.
Inhibition of thromboxane (Tx) synthesis by free radical scavengers. Federation
Proceedings 45:MC47, 1986.
3.
Ischemia induced thromboxane synthesis moderates cardiopulmonary function.
Federation Proceedings 45:1548, 1986.
4.
Kaufman RP Jr, Keane TE, Tucker JA, Hechtman HB, Walther PJ: Acute
testicular ischemia: Pharmacologic reduction of reperfusion injury by prostanoid
modulation. J Urol 143(4):262A, 1990.
5.
Kaufman RP, Carson CC, Robertson CN, Walther PJ. Ureteroscopic
management of transitional cell carcinoma of the ureter using the Nd:YAG laser.
Lasers in Surgery and Medicine (Supplement) 3:324, 1991.
6.
McCandless BK, Kaufman RP Jr., Reddy P., Neumann P, Malik AB: Thrombin
Mediates Neutrophil (PMN) Uptake in Lungs by Proteolytic Action on the Thrombin
Receptor. The FASEB Journal 7:1988, 1993.
7.
Kaufman RP, Jr., McCandless BK, Reddy P., Neumann P., and Malik AB:
Thrombin Induces Renal Microvascular Neutrophil (PMN) Uptake Through a
Receptor-Mediated Event. J. Urol. 149:372, 1993.
8.
Sutherland RW, Barada JH, Kaufman RP, Jr., Fisher HAG: Percutaneous
Puncture of Continent Urinary Reservoirs for Stone Manipulation. J. Urol. 149:743,
1993.
9.
Russell DJ, Kaufman RP, Jr., Cain MP: Medical Management of Benign Prostatic
Hyperplasia (BPH) Versus Transurethral Prostatectomy: The Economic
Consequences. J. Urol. 149:883, 1993.
10.
Perrotti M, Gentle D, and Kaufman R.P., Jr.: Mini-Lap Pelvic Lymph Node
Dissection (MLPLND) Minimizes Morbidity, Cost, and Hospitalization of Pelvic
Lymph Node Dissection (PLND). J. Urol. 151:1084, 1994.
11.
Kallakury BVS, Figge J, Leibovich B, Rifkin M, Kaufman R, Figge HL, Nazeer T,
Ross JS: Increased BCL-2 Protein Levels in Prostatic Adenocarcinomas are not
Associated with Rearrangements in the 2.8 KB Major Breakpoint Region or with P53
Protein Accumulation. Laboratory Investigation 72(1):78A, 1995.
12.
Reddy PP, Russell DJ, Wilbur HJ, Kaufman RP, Jr.: Laser Irradiation Decreases
Local Recurrence in Superficial Bladder Tumors. Lasers in Surgery and Medicine
(Supplement), 7:311, 1995.
13.
Perrotti M, Fisher HAG, Kaufman RP, Jr, Rifkin M.: Assessment of Preoperative
Endorectal Surface Coil Magnetic Resonance Imaging (MRI) of the Male Pelvis as
a Predictor of Final Stage in Clinical Stage T1C, T2A and T2B Adenocarcinoma of
the Prostate. J. Urol., 153:503, 1995.
24
14.
Fisher HAG, Kaufman RP, Jr, Wilbur HJ.: Neoadjuvant Chemotherapy with 5Fluorouracil (5-FU) and Cis-Platin (DDP) for Stage III (N+) Penile Cancer prior to
Ilioinguinal Lymph Node Dissection (ILND) - Long Term Results. J. Urol., 155:59,
1996.
15.
White MD, Gentle DL, Kaufman RP, Jr, Das A, Fisher HAG, Mehlhaff BA:
Outpatient Transurethral Vaporization of the Prostate (TUVP) as a Safe,
Efficacious and Economical Alternative to Standard Transurethral Resection of the
Prostate (TURP). J. Urol., 155:1042, 1996.
16.
Wharton JM, Chieng DC, Hou J, DelRosario AD, Sheehan CS, Fisher HAG,
Kaufman R, Ross JS.: Expression of Transforming Growth Factor Beta (TGF-β):
Transforming Growth Factor Alpha (TGF-α) and Epidermal Growth Factor Receptor
(EGFR) in Renal Cell Carcinoma (RCC). J. Urol., 155:1379, 1996.
17.
Kallakury BVS, Figge J, Yang F, Smith KE, Kausik SJ, Fisher HAG, Kaufman R,
Figge H, Ross JS: Down-Regulation of CD44 Protein in mRNA in Prostate Cancer:
Correlation with Tumor Grade and Ploidy. J. Urol., 155:1534, 1996.
18.
Kallakury BVS, Figge J, Yang F, Smith KE, Kausik SJ, Fisher HAG, Kaufman R,
Figge H, Ross JS: Down-Regulation of CD44 Protein in mRNA in Prostate Cancer:
Correlation with Tumor Grade and Ploidy. (Abstract) Modern Pathol 9(1):430, 1996.
19.
Ross JS, Sheehan CE, Hayner-Buchan, Ambros RA, Kallakury BVS, Kaufman RP
Jr., Fisher HAG, Muraca PJ. HER-2/neu Gene Amplification Status in Prostatic
Cancer (PC) by Fluorescence In-situ Hybridization (FISH). Am J Hum Genet
59:a80, 1996.
19.
Reddy PP, Russell DJ, Wilbur HJ, Kaufman RP Jr.: Laser Irradiation Decreases
Local Recurrence in Superficial Bladder Tumors. BiOs '96 Technical Abstract
Digest, 2671G-70.
20.
Reddy PP, Kaufman RP Jr., Brien TP, McCandless BK, Saba TM: Neutrophil
CD18 Integrin Expression and Matrix Fibronectin Disruption: Mechanisms for
Neutrophil Mediated Intrarenal Vascular Injury. J. Urol., 157:119, 1997.
21.
White MD, Loughlin MW, Fisher HAG, Kaufman RP Jr., Das AK: Voiding Function
in Patients Undergoing Prostatic Cryoablation -- A Preoperative Urodynamic
Analysis. J. Urol., 157:982, 1997.
22.
Groudine SB, Fisher HAG, Kaufman RP Jr., Patel MK, Wilkins L, Mehta SA, Lumb
PD: Intravenous Lidocaine Speeds the Return of Bowel Function, Decreases
Postoperative Pain, and Shortens Hospital Stay in Patients Undergoing Radical
Retropubic Prostatectomy. Anesthesiology, 87:3A, A804, 1997.
23.
Reddy PP, Kaufman RP, Jr., Brien TP, McCandless BK, Saba T: Neutophil CD18
Integrin Expression and Matric Fibronectin Disruption: Mechanisms for Neutrophil
Mediatred Intrarenal Vascular Injury. B.J. Urol. 80, Suppl. 2: 456, 1997.
24.
Loughlin MW, White MD, Kaufman RJ, Jr., Figge J, Dharia N, Fisher HAG:
Neoadjuvant Androgen Deprivation Therapy (ADT) Prior to Radical Prostatectomy
(RP) Decreases Positive Margins for Clinical T1c Prostate Cancer. B.J. Urol. 80,
Suppl. 2: 1047, 1997.
25.
White MD, Loughling MW, Fisher HAG, Kaufman RJ, Jr., Das AK: Voiding
Function in Patients Undergoing Prostatic Cryoablation - A Preoperative
25
Urodynamic Analysis. B.J. Urol. 80, Suppl. 2: 1077, 1997.
26.
Reddy PP, Kaufman RP, Jr., Brien TP, McCandless BK, Saba TM: Renal
microvascular injury during sepsis: CD18 Integrin dependent mechanism of
neutrophil mediated inflammatory response.? Pediatrics, 100, (3) (Suppl); 569,
1997.
27.
Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BVS, Kaufman
R, Fisher HAG, Muraca PJ. HER-2/neu gene amplification status in prostatic
cancer (PC) by fluorescence in-situ hybridization. Modern Pathol 10(1):87A, 1997.
28.
Kallakury BVS, Sheehan CE, Ambros RA, Fisher HAG, Kaufman R, Ross JS.
Prognostic significance of P34cdc2 cyclin dependent kinase and cyclin D1
protein expression in prostatic adenocarcinomas (PACs). Modern Pathol
10(1): 79A, 1997.
29.
Kallakury BVS, Brien TP, Lowry CV, Fisher HAG, Kaufman R, Rifkin MD, Ross JS.
Telomerase activity in benignprostate tissue and prostatic adenocarcinomas
(PACs). Modern Pathol 10(1): 78A, 1997.
30.
Das AK, White MD, Fisher HAG, Kaufman RP, Jr.: Pre and postoperative
urodynamic findings in patients undergoing prostatic cryoablation after radiation
failure. J. Urol., 159:467, 1998.
31.
Kallakury BVS, Sheehan CE, Rhee S, Fisher HAG, Kaufman RP, Jr., Rifkin MD,
Ross JS. Prognostic significance of cell cycle regulatory proteins (cyclins A and B)
and proliferation associated antigens (p120, Ki-67, and PCNA) in prostatic
adenocarcinomas. Modern Pathology 11(1); 86A; 1998.
32.
Kogan BA, Abrahams MH, Kaufman RP, Jr.: Antonio Scarpa: Contributions of a
great surgeon and anatomist. J. Urol., 161:719, 1999.
33.
Abrahams MH, Fisher HAG, Kaufman RP, Jr., Graber MW, Sheehan CE, Ross
JS: Prognostic significance of topoisomerase II alpha overexpression in transitional
cell carcinoma of the urinary bladder. J. Urol., 161:463, 1999.
34.
Ross JS, Sheehan CE, Abrahams HM, Fisher HAG, Kaufman RP, Jr., Rifkin MD,
Kallakury BVS. Decreased expression of e-cadherin and catenin complex proteins
in prostatic adenocarcinomas. Modern Pathology 12(1); 105A; 1999.
35.
Sheehan CE, Chang T, Kallakury BVS, Croce C, Dincer A, Fisher HAG, Kaufman
RP, Jr., Rifkin MD, Ross JS. FHIT tumor suppressor protein expression in prostate
cancer. Modern Pathology 12(1); 107A;
36.
Graber MW, Abrahams HM, Sheehan CE, Fisher HAG, Kaufman RP, Jr., Ross
JS. Prognostic significance of topoisomerase II alpha overexpression in transitional
cell carcinoma of the urinary bladder. Modern Pathology 12(1); 96A; 1999.
37.
Graber MW, Abrahams HM, Sheehan CE, Fisher HAG, Kaufman RP, Jr., Ross
JS. Clinical significance of HER-2/neu amplification and expression in transitional
cell carcinoma of the urinary bladder. Modern Pathology 12(1); 96A; 1999.
38.
Abrahams MH, Strope S, Fisher HAG, Kaufman RP, Jr.: The significance of the
location of positive margins after radical prostatectomy. J. Urol., 163:820, 2000.
26
39.
Murray BP, Fisher HAG, Kaufman RP, Jr.: Endorectal MRI: Assessment of the
utility for prostate cancer localization. J. Urol., 163:845, 2000.
40.
Kaufman RP, Jr., Strope S, Abrahams MH, Fisher HAG: Role of external beam
radiation therapy in pT3 prostate cancer. J. Urol., 163:1162, 2000.
41.
Graber MW, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman RP, Jr., Ross
JS. Expression of the c-kit receptor and its ligand stem cell factor in transitional cell
carcinoma of the urinary bladder. Modern Pathology, 13(1); 578A; 2000.
42.
Kallakury BVS, Sheehan CE, Boehm JR, Fisher HAG, Kaufman RP, Jr., Rifkin MD,
Ross JS. Cell adhesion molecule interactions in prostatic adenocarcinomas
(PACs): Correlation of CD33s downregulation and HER-2/neu amplification with ecadherin/catenin protein expression. Modern Pathology, 13(1); 657A; 2000.
43.
Karikehalli S, Kallakury BVS, Sheehan CD, Bratslavsky G, Kaufman RP, Jr., Fisher
HAG, Ross JS. Patterns of c-kot proto oncogene product expression in renal cell
carcinoma: Coexpression with stem cell factor (SCF) and correlation with high
grade malignancy. Modern Pathology, 13(1); 659A; 2000.
44.
Karikehalli S, Kallakury BVS, Sheehan CE, Bratslavsky G, Kaufman RP, Jr., Fisher
HAG, Ross JS. Loss of expression of PTEN nm23-H1 and KAI-1 tumor
suppressor gene products in renal cell carcinomas (RCCs). Modern Pathology,
13(1); 660A; 2000.
45.
Kaur P, Kallakury BVS, Sheehan CE, Strope SA, Fisher HAG, Kaufman RP, Jr.,
Ross JS. Loss of expression of c-met gene product in human prostatic
adenocarcinoma (PACs) correlates with high tumor grade and aneuploidy. Modern
Pathology, 13(1); 661A; 2000.
46.
Graber MW, Kallakury BVS, Sheehan CE, Abrahams MH, Fisher HAG, Kaufman
RP, Jr., Ross JS. Expression of transforming growth factor Beta-3 in transitional
cell carcinoma of the urinary bladder. Modern Pathology, 14(1); 634A, 2001.
47.
Kallakury BVS, Sheehan CE, Lowry CV, Salmon SL, Anand RD, Fisher HAG,
Kaufman RP, Jr., Ross JS. GST-p protein is downregulated in high grade PIN and
prostatic adenocarcinomas (PACs): A preliminary analysis of association with
methylation of the gene promoter. Modern Pathology, 14(1); 651A, 2001.
48.
Karikehalli S, Kallakury BVS, Sheehan CE, Azumi N, Fisher HAG, Kaufman RP,
Jr., Ross JS. Immunoreactivity for ubiquitin is an independent predictor of survival
in renal cell carcinoma (RCC). Modern Pathology, 14(1); 656A, 2001.
49.
Kaur P, Kallakury BVS, Sheehan CE, Smith K, Fisher HAG, Kaufman RP, Jr., Ross
JS. Immunohistochemical expression of survivin and bcl-2 in prostatic
adenocarcinoma (PACs). Modern Pathology, 14(1); 657A, 2001.
50.
Ross JS, Kaur P, Smith K, Sheehan CE, Fisher HAG, Kaufman RP, Jr., Kallakury
BVS. Co-expression of matrix metalloproteinase 2 and tissue inhibitor of matrix
metalloproteinase 2 in prostatic adenocarcinomas (PACs). Modern Pathology,
14(1); 705A, 2001.
51.
Ross JS, Kallakury BVS, Sheehan CE, Salmon SL, Anand RD, Fisher HAG,
Kaufman RP, Jr., Lowry CV. Immunohistochemical downregulation of GST-pi
protein and methylation of the gene promoter are associated with majority of
27
prostatic adenocarcinomas (PACs). Proceedings of the American Association for
Cancer Research, February 2001.
52.
Lehr DJ, Kaufman RP, Jr.: Coaguloop and wedge loops offers safe and
efficacious outpatient TURP. Canadian Journal of Urology; 9(4):1617, 2002.
53.
White R, Kaufman RP, Jr.: Initial experience with hand-assisted laparoscopic
nephrectomy. Canadian Journal of Urology; 9(4):1618, 2002.
54.
Moore C, Anwar S, Nazeer T, Fisher HAG, Kaufman RP, Jr., Mian BM: Detection
of prostate cancer in men undergoing repeat prostate biopsy: effect of extended
biopsy scheme. Canadian Journal of Urology; 9(4),1619, 2002.
55.
Moore CK, Karekehalli S, Nazeer T, Fisher HA, Kaufman RP, Jr., Mian BM:
Prognostic Value of High Grade Prostatic Intraepithelial and Neoplasia and Atypia in
the Extended Prostate Biopsy Era. J. Urol., 169:453, 2003.
56.
Moore CK, Mian B, Fisher H, Kaufman R, Karekehalli S, Nazeer T: Prognostic
Value of High Grade Prostatic Intraepithelial and Neoplasia and Atypia in the
Extended Prostate Biopsy Era. The Canadian Journal of Urology; 10(4):1953,
August 2003.
57.
White RG, Fisher HA, Kaufman RP, Jr., Upper Tract Transitional Cell Carcinoma:
Outcomes of Ureteroscopic and Percutaneous Approach. The Canadian Journal of
Urology; 10(4):1960, August 2003.
58.
White RG, Kaufman RP, Jr.: Critical Assessment of Hand Assisted Laparoscopic
Nephrectomy (HALN) by the Non-Fellowship Trained Laparoscopist: Initial
Outcomes in Learning Curve. The Canadian Journal of Urology; 10(4):1964,
August 2003.
59.
Karikehalli S, Kallakury BVS, Sheehan CE, Azumi N, Kaufman RP, Jr., Fisher
HAG, Ross JS. Expression of anti-apoptotic proteins surviving and bcl-2 in renal
cell carcinoma (RCC). Modern Pathology 16; 138A, 2003.
60.
Kaur P, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman, Jr. RP, Ross JS.
Expression of heat shock proteins in prostate carcinoma. Modern Pathology 17;
161A-162A, 2004.
61.
Ross JS, Sheehan CE, Kaur P, Fisher HAG, Kaufman, Jr. RP, Kallakury BVS.
Downregulation of CD138 and CD10 in prostatic adenocarcinomas (PACS): Utility
of CD138 as a basal cell marker in prostate tissue. Modern Pathology 17; 174A,
2004.
62.
Capello SA, Kogan BA, Kaufman RP, Jr., Giorgi LJ, Jr. A Retrospective Analysis
of Pyeloplasty in New York State: a 19 Year Review. The Canadian Journal of
Urology; 11(4): 2354, August 2004.
63.
Bratslavsky G, Fisher HAG, Kaufman RP, Jr., NazeerT, Mian B Percent Free
Prostate Specific Antigen in the Extended Biopsy Era: Still Relevant?, The Canadian
Journal of Urology; 11(4): 2362, August 2004.
64.
Capello SA, Kaufman RP, Jr., Fisher HAG, Mian B, Tolerability and Efficacy of
Bicalutamide Monotherapy in Biochemical Recurrence of Prostate Cancer, The
Canadian Journal of Urology, 11(4): 2373, August 2004.
28
65.
Capello SA, Kogan BA, Giorgi LJ, Jr., Kaufman RP, Jr., Prenatal Ultrasound
Reduces the Rate of Adult Pyeloplasty J. Urol. 173(4) Suppl. 89, 2005.
66.
Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman Jr. RP, Ross JS.
Immunohistochemical Expression Of Ezh2 In Prostatic Adenocarcinomas (Pacs).
Modern Pathology, 18(149A); 2005.
67.
Ross JS, Sheehan GM, Sheehan CE, Fisher HAG, Kaufman Jr. RP, Kallakury
BVS. SMAD4 Protein Is Expressed In Prostatic Adenocarcinomas (Pacs) And
Correlates With Grade, Stage And DNA Ploidy. Modern Pathology
18(161A);2005.
68.
Kallakury BVS, Sheehan GM, Sheehan CE, Fisher HAG, Kaufman Jr. RP, Ross
JS. Increased Stat3 And Stat5 Protein Expression Correlates With Aggressive
Biologic Phenotype In Prostatic Adenocarcinomas (Pacs). Modern Pathology,
18(149A); 2005.
69.
Conners III WP, Kaufman R. Outcomes with the Prolieve Thermodilation System
for BPH. CUAJ, 1 (3) (9): 2007.
70.
Conners III WP, Kaufman R. Androgen Replacement Therapy After Prostate
Cancer. CUAJ, 1 (3) (29): 2007.
71.
Conners W, Kaufman R. Androgen Replacement Therapy After Prostate Cancer.
J Sex Med, 5(suppl 1)(59); 2008
72.
Feuerstein MA, Nazeer T, Fisher H, Kaufman Jr. R, Mian BM. Gleason Grade at
the Surgical Margin: Correlation with Primary Gleason Grade and Recurrence.
CUAJ, 2 (4) (13): 2008.
73.
Chughtai B, Kaufman Jr. RP, Fisher HAG, Mian B. Role of Biopsy in the
Management of Small Renal Masses. CUAJ, 2 (4) (42): 2008.
74.
Chughtai B, Kaufman Jr. R, Fisher HAG, Sisken G, Mian BM. Role of Biopsy in the
Management of Small Renal Masses. J.Urol., 181(4): 687, 2009.
75.
Feurstein MA, Hong M, Nazeer T, Fisher H, Kaufman Jr R, Mian BM.
Comparison of Tertiary Center and Referred Prostate Biopsies: Impact of ReReview on Gleason Score Accuracy. CUAJ, 3 (5 Suppl3) (15); 2009.
76.
Fisher H, Kaufman R, Morton RA. Toremifene 80 mg Phase 3 Trial in Men on
ADT Demonstrates Improvement in Gynecomastia Compared to Placebo. CUAJ,
3 (5 Suppl3) (98); 2009.
77.
Chughtai B, Kaufman Jr. RP, Fisher HAG, Sisken G, Mian B. Role of Biopsy in the
Management of Small Renal Masses. CUAJ, 3 (5 Suppl3) (120); 2009
78.
Feurstein MA, Mian BM, Fisher Hugh, Kaufman Ronald Jr. Percutaneous Ablation
of Renal Masses: The Albany Medical Center Experience. CUAJ, 4(5
Suppl2)(30); 2010.
79.
Aliotta Philip J, Kaufman Ronald, Brawer Michael, Morton Ronald A, Chazen Mark
D, Pinski John V. Toremifene 80 mg Demonstrates Reduction in Fracture Risk in
Men who are Less Than 80 Years of Age on Androgen Deprivation Therapy.
CUAJ, 4(Suppl2);2010
29
80.
Feuerstein Michael, Hasak Stephen, Kaufman Ronald Smaller Tumor Size is a Risk
Factor for Positive Margins in Partial Nephrectomy. CUAJ, 5(5Suppl3)(54); 2011
PRESENTATIONS:
1.
"Indirect immunofluorescence technique for demonstration of estrogen receptor
protein in benign liver tumors." Annual Hartford Hospital Summer Student Fellowship
Research Day, August, 1978.
2.
"The effects of the neonatal administration of dihydrotestosterone (DHT) on
aggression in mice." Trinity College Department of Biology Annual Student
Research Day, May, 1979.
3.
"Evidence that thymic peptides may provide a link in the neural modulation of the
immune system." Annual Medical Student Research Day, sponsored by the William
Beaumont Medical Society, March, 1981.
4.
"Vasodilator prostaglandins (PG) prevent renal damage after ischemia." Surgical
Forum, American College of Surgeons, Chicago, IL, 1985.
5.
"Prostanoid mediators of ischemic injury." Surgical Research Conference
Department of Surgery, Brigham and Women's Hospital, Boston, MA, October,
1985.
6.
"Inhibition of thromboxane (Tx) synthesis by free radical scavengers."
Microcirculatory Society, St. Louis, MO, 1986.
7.
"Protection against renal ischemia by increasing plasma PG/Tx." FASEB, St. Louis,
MO, 1986.
8.
"Pathophysiology of ureteral obstruction." Urologic Teaching Conference,
Department of Surgery/Division of Urology, Duke University Medical Center,
Durham, North Carolina, 1988.
9.
"Testicular Torsion and Trauma." Urologic Teaching Conference, Department of
Surgery/Division of Urology, Duke University Medical Center, Durham, North
Carolina, 1988.
10.
"Management of Renal Trauma." Urologic Teaching Conference, Department of
Surgery/Division of Urology, Duke University Medical Center, Durham, North
Carolina, 1989.
11.
"Acute Testicular Ischemia: Pharmacologic Reduction of Tissue Injury by
Prostanoid Modulation." The Montague L. Boyd Prize Essay Contest, Southeastern
Section American Urologic Association, West Palm Beach, FL, 1990.
12.
"Acute Testicular Ischemia: Pharmacologic Reduction of Reperfusion Injury by
Prostanoid Modulation." American Urological Association, New Orleans, LA, 1990.
13.
"A pharmacologically-induced increased plasma prostacycline (PGI2) to
thromboxane (TxA2) ratio protects the testis from ischemic necrosis." Surgical
Forum, American College of Surgeons, San Francisco, CA, 1990.
14.
"Ureteroscopic management of transitional cell carcinoma of the ureter using the
Nd:YAG laser." Southeastern Section American Urologic Association, Atlanta, GA,
1991.
30
15.
"Ureteroscopic management of transitional cell carcinoma of the ureter using the
Nd:YAG laser." American Society for Laser Medicine and Surgery, San Diego, CA,
1991.
16.
"Adenocarcinoma of the prostate: tumor markers." Department of Surgery Grand
Rounds, Albany Medical College, Albany, New York, November 1991.
17.
"The role of prostate specific antigen in benign and malignant prostatic diseases."
Department of Surgery
and Office of Continuing Medical Education, Current Management of Prostatic
Diseases, Albany Medical College, Albany, New York, November 1991.
18.
Department of Internal Medicine Grand Rounds, Albany Medical College, Albany,
New York, February 1992.
19.
"Adenocarcinoma of the prostate: tumor markers." Binghamton Internal Medicine
Symposium, Binghamton, New York, July 1992.
20.
"Quinolone update - a urologist's perspective." Dinner meeting with Mary Imogene
Bassett and Oneonta physicians, Leonardsville, New York, September 1992.
21.
"The medical management of benign prostatic hyperplasia; it's economic
consequences." Northeastern Section American Urological Association, Toronto,
Ontario, Canada, 1992.
22.
"The prognostic value of serum prostate specific antigen levels in stage D2 prostate
cancer treated by castration." Northeastern Section American Urological
Association, Toronto, Ontario, Canada, 1992.
23.
"The management of renal cell carcinoma with renal vein and vena cava tumor
thrombus." Department of Surgery Grand Rounds, Albany Medical College, Albany,
New York, September 1992.
24.
"What a urologist does." Quarterly meeting, Northeastern New York Searle
Pharmaceutical Representatives, Desmond Americana, Albany, New York, October
1992.
25.
"The role of Quinolones in the management of urinary tract infections." Round table
discussion, Stone Ends Restaurant, Albany, New York, October 1992.
26.
"Neutrophil (PMN) CD18 integrin mediates endotoxin induced intrarenal PMN
sequestration." Surgical Forum, American College of Surgeons, New Orleans,
Louisiana, 1992.
27.
"The clinical importance of early diagnosis of prostate cancer." Prostate ultrasound
course, Department of Radiology, Albany Medical College, Albany, New York,
October 16, 1992.
28.
discussion, The Old Daley Inn, Troy, New York, October 20, 1992.
29.
discussion, Deckers Restaurant, Syracuse, New York, October 26, 1992.
31
30.
"The management of simple and complicated urinary tract infection." Department of
Family Practice, Gannett Health Center, Ithaca, New York, October 29, 1992.
31.
"The role of Quinolones in the management of simple and complicated urinary tract
infections." Dinner meeting, L'Auberge du Cochan Rouge, Ithaca, New York,
October 29, 1992.
32.
"The management of simple and complicated urinary tract infections." Department
of Medicine Grand Rounds, Scottsdale Memorial Hospital, Scottsdale, Arizona,
November 2, 1992.
33.
"The role of Quinolones in the management of simple and complicated urinary tract
infections." Dinner meeting, American Bar and Grill, Mesa, Arizona, November 2,
1992.
34.
Department of Medicine Grand Rounds, Samaritan Hospital, Troy, New York,
November 5, 1992.
35.
"Adenocarcinoma of the prostate: tumor markers." Department of Family
Practice, Albany Medical College, Albany, New York, November 9, 1992.
36.
"Evaluation and management of testicular pain." Emergency Treatment Associates,
Grand Rounds, The Ship's Lantern Inn, Milton, New York, November 11, 1992.
37.
"Quinolone Update - A urologist's Perspective." Dinner meeting, Luigi's Restaurant,
Schenectady, New York, November 19, 1992.
38.
"The Role of Prostate Specific Antigen in Benign and Malignant Prostatic
Diseases." Department of Nephrology Grand Rounds, Albany Medical College,
Albany, New York, December 8, 1992.
39.
"The Management of Simple and Complicated Urinary Tract Infections." Dinner
meeting, Veronica's Restaurant, Roxbury, New York, December 10, 1992.
40.
"Evaluation and Treatment of Simple and Complex Tract Infections." Dinner
meeting, Thatcher's Restaurant, Albany, New York, December 16, 1992.
41.
"The Management of Simple and Complicated Urinary Tract Infections."
Department of Medicine Grand Rounds, Samaritan Hospital, Troy, New York,
January 21, 1993.
42.
"The Role of Quinolones in the Management of Simple and Complicated Urinary
Tract Infections." Dinner meeting, Mont Calm Inn, Glens Falls, New York, March 4,
1993.
43.
"Evaluation and Treatment of Simple and Complex Urinary Tract Infections." The
5th annual Adirondack Society of Physicians' Assistants, Winter CME Weekend,
Holiday Inn, Lake Placid, New York, March 7, 1993.
44.
"The Role of Quinolones in the Management of Simple and Complicated Urinary
Tract Infections." Dinner meeting, Anthony's Restaurant, Plattsburgh, New York,
March 11, 1993.
32
45.
"The Management of Renal Cell Carcinoma with Renal Vein and Vena Cava Tumor
Thrombus." Utica Urologic Society, Horned Dorsett Restaurant, Leonardsville, NY,
March 25, 1993.
46.
"Thrombin Mediates Neutrophil (PMN) Uptake in Lungs by Proteolytic Action on the
Thrombin Receptor." FASEB, New Orleans, Louisiana, March 30, 1993.
47.
"Management of Renal Trauma." Emergency Treatment Associates, Grand
Rounds, The Culinary Institute, Hyde Park, New York, April 14, 1993.
48.
"The Clinical Importance of the Early Diagnosis of Prostate Cancer." Prostate
Ultrasound Course, Dept. of Radiology, Albany Medical College, Albany, New York,
April 16, 1993.
49.
"Quinolone Update - A Urologist's Perspective." Round Table Discussion, The
Crooked Lake House, Troy, New York, April 30, 1993.
50.
"The Role of Quinolones in the Management of Complicated Urinary Tract
Infections." Round Table Discussion, Brennan's Restaurant, Elmira, New York, May
6, 1993.
51.
"The Management of Simple and Complicated Urinary Tract Infections." Dept. of
Medicine Grand Rounds, The Bath Veteran's Administration Medical Center, Bath,
New York, May 7, 1993.
52.
"The Management of Simple and Complicated Urinary Tract Infections." Dept. of
Medicine Grand Rounds, St. Joseph's Hospital, Elmira, New York, May 7, 1993.
53.
"Adenocarcinoma of the Prostate: Tumor Markers." Dept. of Medicine Grand
Rounds, St. Elizabeth's Hospital, Utica, New York, May 11, 1993.
54.
"Thrombin Induces Renal Microvascular Neutrophil (PMN) Uptake Through a
Receptor Mediated Event." American Urological Association, San Antonio, Texas,
1993.
55.
"Percutaneous Puncture of Continent Urinary Reservoirs for Stone Manipulation."
American Urological Association, San Antonio, Texas, 1993.
56.
"Medical Management of Benign Prostatic Hyperplasia (BPH) Versus Transurethral
Prostatectomy: The Economic Consequences." American Urological Association,
San Antonio, Texas, 1993.
57.
"Continent Diversion." Contemporary Topics in Urology: 1993, Fort Orange Club,
Albany, New York, June 10, 1993.
58.
"The Role of Quinolones in the Management of Complicated Urinary Tract
Infections." Dinner Meeting, Malone, New York, June 23, 1993.
59.
"PSA-What Does It Mean?" Albany Medical College Prostate Cancer Support
Group, Albany Medical Center, June 30, 1993.
60.
"The Clinical Importance of Early Diagnosis of Prostate Cancer." Prostate and
Urinary Tract Ultrasound Course, Department of Radiology, Albany Medical
College, Albany, New York, July 16, 1993.
61.
"Continent Diversion." International Urological Sciences Urology Workshop,
33
National Conference, Mid-Atlantic Region, Albany, New York, September 23, 1993.
62.
"Thrombin Induced Expression of Neutrophil (PMN) CD18 Integrin: A Mechanism
for Intrarenal PMN Sequestration." Surgical Forum, American College of Surgeons,
San Francisco, CA, October 11-15, 1993.
63.
"What The Urologist Needs To Know Before Ordering A Prostate Ultrasound."
Prostate Ultrasound Course, Department of Radiology, Albany Medical College,
Albany, New York, October 29, 1993.
64.
"Mini Laparotomy Minimizes Morbidity of Pelvic Lymph Node Dissection."
Northeastern Section American Urologic Association, San Juan, Puerto Rico,
November 10-12, 1993.
65.
"Gleason Sum of Nine Does Not Predict Lymphatic Spread in Prostatic
Adenocarcinoma." Northeastern Section American Urologic Association, San
Juan, Puerto Rico, November 10-12, 1993.
66.
"The Diagnosis and Management of BPH." Medical Grand Rounds, North Adams
Regional Hospital, North Adams, Massachusetts, February 1, 1994.
67.
"Current Concepts in the Diagnosis and Management of Prostate Cancer." Medical
Grand Rounds, North Adams Regional Hospital, North Adams, Massachusetts,
February 1, 1994.
"Continent Urinary Diversion." Department of Surgery Grand Rounds, Albany
Medical College, Albany, New York, February 3, 1994.
68.
69.
"Benign Prostatic Hyperplasia: A Clinical Perspective." Daytona Beach Area
Urologic Association, Le Crepe En Haut, Ormond Beach, Florida, March 17, 1994.
70.
"Mini Laparotomy Pelvic Lymph Node Dissection," Daytona Beach Area Urologic
Association, Halifax Club, Daytona Beach, Florida, March 18, 1994.
71.
"Incontinence and Impotence As They Relate To Prostate Cancer," Prostate
Cancer "Us Too" Support Group, Albany Medical Center, Albany, New York, March
30, 1994.
72.
"Continent Urinary Diversion," Utica Area Urologic Association, The Ramada Inn,
Utica, New York, March 31, 1994.
73.
"What the Urologist Needs to Know Before Ordering A Prostate Ultrasound,"
Albany, New York, April 15, 1994.
74.
"Diagnosis and Management of BPH," Vestal Steakhouse, Vestal, New York, April
21, 1994.
75.
"Advances in the Management of Benign Prostatic Hyperplasia", Innocenzo's
Restaurant, New Hartford, New York, April 28, 1994.
76.
"Diagnosis and Management of BPH", Poplar's Restaurant, Fonda, New York, May
2, 1994.
77.
"Mini-Lap Pelvic Lymph Node Dissection (MLPLND) Minimizes Morbidity, Cost, and
Hospitalization of Pelvic Lymph Node Dissection (PLND)." American Urological
Association, San Francisco, California, May 14-19, 1994.
34
78.
"Current Diagnosis and Management of BPH", Captain's Lounge, Oswego, New
York, June 8, 1994.
79.
"Diagnosis and Management of BPH", Gloversville Medical Society, Kingsboro
Country Club, Gloversville, New York, June 15, 1994.
80.
"Management of Benign Prostatic Hyperplasia in the 1990's", Massena Medical
Society, Violis Restaurant, Massena, New York, June 21, 1994.
81.
"Diagnosis and Management of BPH", Schoharie Medical Society, Summit Room,
Delanson, New York, August 3, 1994
82.
"Management of Benign Prostatic Hyperplasia in the 1990's", Urology Teaching
Day, Binghamton General Hospital, Binghamton, New York, August 31, 1994.
83.
"Advances in the Management of Benign Prostatic Hyperplasia", Oswego Medical
Society, Captain's Lounge, Oswego, New York, September 13, 1994.
84.
"Prostate Cancer in the 1990's", Prostate Cancer "Us Too" Support Group, Albany
Medical Center, Albany, New York, September 21, 1994.
85.
"Assessment of Preoperative Endorectal Surface Coil Magnetic Resonance
Imaging of the Male Pelvis as a Predictor of Final Stage in Clinical Stage B or T1C
Adenocarcinoma of the Prostate", Northeastern Section American Urologic
Association, Sagamore Resort, Lake George, New York, September 25-28, 1994.
86.
"Assessment of Serum Prostate Specific Antigen as an Independent Predictor of
Lymph Node Metastases in Clinically Localized Adenocarcinoma of the Prostate",
Northeastern Section American Urologic Association, Sagamore Resort, Lake
George, New York, September 25-28, 1994.
87.
"Follow-Up of T4 Transitional Cell Carcinoma of the Bladder After Radical
Cystoprostatectomy and Total Urethrectomy", Northeastern Section American
Urologic Association, Sagamore Resort, Lake George, New York, September 2528, 1994.
88.
"An Update in the Treatment of Benign Prostatic Hyperplasia", Coachman
Restaurant, Glens Falls, New York, November 8, 1994.
89.
"The Diagnosis and Management of BPH in the 90's", Visiting Professor, MidHudson Family Health Services Institute, Kingston Hospital, Kingston, New York,
November 18, 1994.
90.
"Management of Benign Prostatic Hyperplasia in the 1990's", Medical Grand
Rounds, St. Elizabeth Hospital, Utica, New York, January 17, 1995.
91.
"Cryotherapy of Prostate Cancer", Utica Urologic Association, Symeons'
Restaurant, Utica, New York, January 17, 1995.
92.
"What the Urologist Needs to Know Before Ordering a Prostate Ultrasound",
Prostate Ultrasound Course, Dept. of Radiology, Albany Medical College, Albany,
New York, March 17, 1995.
93.
"Percutaneous Transperineal Ultrasound Guided Prostatic Cryoablation", AMC/RPI
Joint Research Symposium, Albany Medical College, Albany, New York, March 25,
35
1995.
94.
"Laser Irradiation Decreases Local Recurrence in Superficial Bladder Tumors",
American Society for Laser Medicine and Surgery, San Diego, California, April
1995.
95.
"Management of Benign Prostatic Hyperplasia in the 1990's", Medical Grand
Rounds, Whitney M. Young Health Center, Albany, New York, April 5, 1995.
96.
"The Pathophysiology, Diagnosis, Management, and Treatment Options for Benign
Prostatic Hyperplasia in the 1990's", Pfizer Representative Training Conference,
Best Western Hotel, Albany, New York, April 7, 1995.
97.
"Assessment of Preoperative Endorectal Surface Coil Magnetic Resonance
Imaging (MRI) of the Male Pelvis as a Predictor of Final Stage in Clinical Stage
T1C, T2A and T2B Adenocarcinoma of the Prostate", American Urological
Association, Las Vegas, Nevada, April 25, 1995.
98.
"Advances in the Diagnosis and Treatment of Benign Prostatic Hyperplasia", Family
Practice Grand Rounds, St. Clare's Hospital, Schenectady, New York, May 23,
1995.
99.
"Diagnosis and Treatment of Benign Prostatic Hyperplasia in the 1990's", Upstate
Urologic Surgeons Quarterly Conference, Lake Placid Lodge, Lake Placid, New
York, June 24, 1995.
100.
"The Diagnosis, Management and Treatment Options for Benign Prostatic
Hyperplasia in the 1990's", Mid-Hudson Urologic Association Quarterly Meeting,
Ship's Lantern Inn Restaurant, Milton, New York, June 27, 1995.
101.
"The Diagnosis, Management and Treatment Options for Benign Prostatic
Hyperplasia in the 1990's", Albany Medical College Internal Medicine Noon Time
Grand Rounds, Albany Medical College, Albany, New York, July 20, 1995.
102.
Albany, New York, July 23, 1995.
103.
"The Diagnosis, Management, and Treatment Options for Benign Prostatic
Hyperplasia in the 1990's", Albany Medical College Department of Family Practice
Monthly Grand Rounds, Ogden's Restaurant, Albany, New York, July 24, 1995.
104.
"The Medical and Surgical Management of BPH", Innovations in the Diagnosis and
Treatment of Benign Prostatic Hyperplasia, Omni Sagamore Resort, Bolton
Landing, New York, August 5, 1995.
105.
"PROTECT: A New System for the Diagnosis and Management of BPH and
Implications in a Managed Care Setting", Innovations in the Diagnosis and
Treatment of Benign Prostatic Hyperplasia, Radisson Hotel Burlington, Burlington,
Vermont, August 26, 1995.
106.
"The Medical and Surgical Management of BPH", Innovations in the Diagnosis and
Treatment of Benign Prostatic Hyperplasia, Radisson Hotel Burlington, Burlington,
Vermont, August 26, 1995.
107.
"Benign Prostatic Hyperplasia: Epidemiology, Differential Diagnosis and Clinical
36
Management", Allegheny Valley Hospital Medical Grand Rounds, Allegheny Valley
Hospital, Natrona Heights, Pennsylvania, September 1, 1995.
108.
"Early Detection of Prostate Cancer - Does it Make a Difference?", Division of
Urology symposium on Prostate Cancer: Where Do We Stand?, Albany Medical
Center Hospital, Albany, New York, September 7, 1995.
109.
"Comparison of Prostate Specific Antigen to PSA Density and Age Specific PSA for
the Diagnosis of Adenocarcinoma of the Prostate", New England Section American
Urological Association, Marriott Hotel, Newport, Rhode Island, September 15-17,
1995.
110.
Prostate Ultrasound Course, Dept. of Radiology, Albany Medical College, Albany,
New York, October 6, 1995.
111.
"Benign Prostatic Hyperplasia: Epidemiology, Differential Diagnosis, and Clinical
Management", Champlain Valley Physician's Hospital Medical Center Medical
Grand Rounds, Plattsburgh, New York, October 13, 1995.
112.
Management", Department of Medicine Noon-time Grand Rounds, Albany Medical
Center, Albany, New York, October 16, 1995.
113.
Management", Medical Grand Rounds, Wilson Memorial Regional Medical Center,
Johnson City, New York, December 14, 1995.
114.
"Laser Irradiation Decreases Local Recurrence in Suerficial Bladder Tumors", SPIE
The International Society for Optical Engineering, BiOS, 1996, San Jose, California,
January 29, 1996.
115.
"Prostate Cancer: Medical Issues in Evaluating Disability", New York State
Department of Social Services Office of Disability Determinations monthly Grand
Rounds, 1 Commerce Plaza, Albany, New York, February 13, 1996.
116.
Management", Monthly Grand Rounds, Mid-Hudson Family Health Services
Institute, Hillside Manor, Kingston, New York, March 13, 1996.
117.
"Prostate Cancer and Impotence", Albany Medical College Prostate Cancer "Us
Too" Support Group, Albany Medical Center, March 20, 1996.
118.
"Increased BCL-2 Protein Levels in Prostatic Adenocarcinomas are not Associated
with Rearrangements in the 2.8 KB Major Breakpoint Region or with P53 Protein
Accumulation", AMC/RPI Joint Research Symposium, Rensselaer Polytechnic
Institute, Troy, New York, March 23, 1996.
119.
"BPH:Diagnosis and Treatment", Urology Workshop, National Conference, MidAtlantic Region, "Updating Clinical Skills", Ramada Inn, Albany, New York, April 19,
1996.
120.
"Neoadjuvant Chemotherapy with 5-Fluorouracil (5-FU) and Cis-Platin (DDP) for
Stage 3 (N+) Penile Cancer Prior to Ilioinguinal Lymph Node Dissection (ILND) Long Term Results", American Urological Association, Orlando, Florida, May 5,
1996.
37
121.
"Outpatient Transurethral Vaporization of the Prostate (TUVP) as a Safe,
Efficacious and Economical Alternative to Standard Transurethral Resection of the
Prostate (TURP)", American Urological Association, Orlando, Florida, May 7, 1996.
122.
"Expression of Transforming Growth Factor Beta (TGF-β), Transforming Growth
Factor Alpha (TGF-α) and Epidermal Growth Factor Receptor (EGFR) in Renal Cell
Carcinoma (RCC)", American Urological Association, Orlando, Florida, May 8,
1996.
123.
"Down-Regulation of CD44 Protein and mRNA in Prostate Cancer: Correlation with
Tumor Grade and Ploidy", American Urological Association, Orlando, Florida, May
8, 1996.
124.
Management", Rounds table discussion, Parimount Grill, Hudson, New York, June
27, 1996.
125.
"Finasteride Meta-analysis and Five Year Data Assessment", Merck New Jersey
Representatives Update Meeting, Somerset, New Jersey, September 5, 1996.
126.
"Finasteride Meta-analysis and Five Year Data Assessment", Merck New York
Representatives Update Meeting, Albany, New York, September 11, 1996.
127.
"Outpatient Transurethral Vaporization of the Prostate (TUVP) as a Safe,
Efficacious, and Economical Alternative to Standard Transurethral Resection of the
Prostate (TURP)", Northeastern Section American Urological Association, The
Buffalo Hilton Hotel, Buffalo, New York, September 26-29, 1996.
128.
"Neoadjuvant Androgen Deprivation Therapy (ADT) Prior to Radical Prostatectomy
(RP) Decreases Positive Margins for cT1C Prostate Cancer", Northeastern
Section American Urological Association, The Buffalo Hilton Hotel, Buffalo, New
York, September 26-29, 1996.
129.
"Clinical Utility of Free and Total Prostate Specific Antigen Levels", Northeastern
130.
"Neutrophil CD18 Integrin Expression and Matrix Fibronectin Disruption:
Mechanisms for Neutrophil Mediated Intrarenal Vascular Injury", Northeastern
131.
"Medical Management of BPH", BPH and Other Urologic Disorders: A Primary Care
Perspective, Desmond Hotel, Albany, New York, October 12, 1996.
132.
"PROTECT: A Revolutionary System for the Diagnosis and Management of BPH",
BPH and Other Urologic Disorders: A Primary Care Perspective, Desmond Hotel,
Albany, New York, October 12, 1996.
133.
"Continent Urinary Diversion", Management of Benign and Malignant Bladder
Disorders, The Inn at Saratoga, Saratoga Springs, New York, November 1, 1996
134.
"Office Management of Prostate Hyperplasia", Hot Topics in Primary Care 1997,
Killington Resort, Killington, Vermont, March 21, 1997.
38
135.
"Medical Management of BPH and Prostate Cancer Screening", Albany Medical
College Department of Family Practice Monthly Grand Rounds, Capital House
Restaurant, Glenmont, New York, March 24, 1997.
136.
"Early Detection of Prostate Cancer - Does it Make a Difference?", Combined
Urology Grand Rounds, Lacklind Air Force Base, Wilford Hall Medical Center and
Brooke Army Medical Center, San Antonio, Texas, March 26, 1997.
137.
"Prostate Cancer: New Developments in Treatments", The Urological Association
of the Mohawk Valley Monthly Grand Rounds, Lupino's Trackside Restaurant, Utica,
New York, March 27, 1997.
138.
Mechanisms for Neutrophil Mediated Intrarenal Vascular Injury", American
Urological Association, New Orleans, Louisiana, April, 1997.
139.
"Voiding Function in Patients Undergoing Prostatic Cryoablation - A Preoperative
Urodynamic Analysis", American Urological Association, New Orleans, Louisiana,
April, 1997.
140.
"Bladder Cancer Patient Care Evaluation: 1995", Cancer Committee, Albany
Medical Center Hospital, Albany, New York, May 20, 1997.
141.
"Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy
Decreases Positive Margins for CT1C Prostate Cancer", Societe Internationale
d'Urologie, Montreal, Canada, September 9, 1997.
142.
Mechanisms for Neutrophil Mediated Intrarenal Vascular Injury", Societe
Internationale d'Urologie, Montreal, Canada, September 11,
143.
"Voiding Function in Patients Undergoing Prostatic Cryoablation: A Preoperative
Urodynamic Analysis", Societe Internationale d'Urologie, Montreal, Canada,
September 11, 1997.
144.
"Update and Treatment of BPH", Department of Medicine, Medical Grand Rounds,
Sisters of Charity Hospital, Buffalo, New York, October 14, 1997.
145.
"Transurethral Vaporization of the Prostate: An Efficacious and Durable Treatment
for Benign Prostatic Hyperplasia", Surgical Forum, American College of Surgeons,
Chicago, Illinois, 1997.
146.
"Transurethral Vaporization of the Prostate (TUVP) - An Efficacious and Durable
Treatment for Benign Prostatic Hyperplasia (BPH)", Northeastern Section American
Urological Association, The Wigwam Resort, Litchfield, Arizona, October 23-26,
1997.
147.
"Clinical Correlation of DNA Ploidy and Cellular Biomarkers of Preoperative
Prostate Needle Biopsy Specimens to Predict Prostate Cancer Progression",
Northeastern Section American Urological Association, The Wigwam Resort,
Litchfield, Arizona, October 23-26, 1997.
148.
"What's New in the Treatment of Benign Prostatic Hyperplasia", The Cranberry Bog
Restaurant, Albany, New York, November 19, 1997.
149.
"The Diagnosis and Treatment of Benign Prostatic Hyperplasia, Basics for the Non-
39
Urologist", Pfizer Representative Training Conference, Desmond Hotel, Albany,
New York, December 19, 1997.
150.
"Renal Microvascular Injury During Sepsis: CD18 Integren Dependent Mechanism
of Neurophil Mediated Inflammatory Response", American Academy of Pediatrics,
New Orleans, Louisiana, 1997.
151.
"Prostatic Intraepithelial Neoplasia (PIN)", Urology Grand Rounds, Albany Medical
College, Albany, New York, March 12, 1998.
152.
"Diagnosis and Management of Erectile Dysfunction", Hot Topics in Primary Care
1998, Killington Resort, Killington, Vermont, March 27, 1998.
153.
"Case Presentations in Erectile Dysfunction", Pfizer Representative Training
Conference and Erectile Dysfunction Preceptorship, Desmond Hotel, Albany, New
York, April 20, 1998.
154.
"Diagnosis and Management of Erectile Dysfunction", Albany Medical College
Department of Family Practice Monthly Grand Rounds, Thacher's Restaurant,
155.
"Diagnosis and Management of Erectile Dysfunction", Glens Falls Hospital Medical
Grand Rounds, Glens Falls Hospital, Glens Falls, New York, May 5, 1998.
156.
"The Diagnosis and Management of Benign Prostatic Hyperplasia, Long Term
Medical Management Outcomes", The Desmond Hotel, Albany, New York, May 11,
1998.
157.
"Diagnosis and Management of Erectile Dysfunction", Allegro Cafe, Troy, New York,
May 12, 1998.
158.
"The Diagnosis and the Management of Benign Prostatic Hyperplasia, Long Term
Medical Management Outcomes", The Desmond Hotel, Albany, New York, May 14,
1998.
159.
"Diagnosis and Management of Erectile Dysfunction", The Barnsider Restaurant,
Colonie, New York, May 19, 1998.
160.
"The Diagnosis and Treatment of Prostate Cancer", The St. Lawrence County
Medical Society Annual Meeting, Potsdam, New York, May 21, 1998.
161.
"Pre and Postoperative Urodynamic Findings in Patients Undergoing Prostatic
Cryoablation after Radiation Failure", American Urological Association, San Diego,
California, May, 1998.
162.
"Prostatic Intraepithelial Neoplasia (PIN)", The Urological Association of the
Mohawk Valley Monthly Grand Rounds, Horned Dorsett Restaurant, Leonardsville,
New York, June 17, 1998.
163.
"The Diagnosis and Management of Erectile Dysfunction", Hudson Valley
Community College Physician's Assistant Program, Albany Medical College, Albany,
164.
"Evaluation and Treatment of Scrotal and Testicular Pain", Hudson Valley
Community College Physician's Assistant Program, Albany Medical College, Albany,
40
165.
"Impotency: What's New", Department of Medicine Grand Rounds, Albany Medical
College, Albany, New York, June 26, 1998.
166.
"The Diagnosis and Management of Benign Prostatic Hyperplasia", Greater Buffalo
Urological Society Meeting, Niagara Clipper Cruise Boat, Buffalo, New York, July
22, 1998.
167.
"Medical Management of Benign Prostatic Hyperplasia Disease Progression:
PROSCAR Long-Term Efficacy and Safety", The Coachman Restaurant, Lake
George, New York, August 29, 1998.
168.
"Update on Currently Available Clinical Trials for the Treatment of Prostate Cancer
at Albany Medical Center", Huyk Auditorium, Albany Medical Center, Albany, New
York, September 15, 1998.
169.
"Extraperitoneal Flank Approach Minimizes Morbidity and Hospitalization for
Radical Nephrectomy", Northeastern Section, American Urological Association,
The Royal York Hotel, Toronto, Ontario, Canada, October 18-21, 1998.
170.
“Current Management of Advanced Prostate Cancer”, Urology Grand Rounds,
Albany Medical College, Albany, New York, October 29, 1998.
171.
“Diagnosis and Management of Erectile Dysfunction”, Clinical Update in Obstetrics
and Gynecology, Stratton Mountain Inn, Stratton Mountain, Vermont, February 11,
1999.
172.
“Hematuria: Evaluation and Prognosis, Clinical Update in Obstetrics and
Gynecology, Stratton Mountain Inn, Stratton Mountain, Vermont, February 12,
1999.
173.
“Comprehensive Evaluation and Management of Prostatic Hyperplasia”, The
Desmond Hotel, Albany, New York, March 16, 1999.
173. “Comprehensive Update on the Medical Management of Prostatic Hyperplasia”,
The Glasbern Inn, Fogelsville, Pennsylvania, March 29, 1999.
174.
“Comprehensive Update on the Medical Management of Benign Prostatic
Hyperplasia”, Medical Grand Rounds, St. Luke’s Hospital, Allentown, Pennsylvania,
March 30, 1999.
175.
“Erectile Dysfunction Epidemiology and Office Evaluation”, Erectile Dysfunction
and Benign Prostatic Hyperplasia (BPH): Current Diagnosis and Management,
Hilton Garden Inn, Albany Airport, Albany, New York, April 10, 1999.
176.
“Surgical Therapy for Erectile Dysfunction”, Erectile Dysfunction and Benign
Prostatic Hyperplasia (BPH): Current Diagnosis and Management, Hilton Garden
Inn, Albany Airport, Albany, New York, April 10, 1999.
177.
“BPH: Epidemiology, Office Evaluation and Role of PSA”, Erectile Dysfunction and
Benign Prostatic Hyperplasia (BPH): Current Diagnosis and Management, Hilton
Garden Inn, Albany Airport, Albany, New York, April 10, 1999.
178.
“Update on Urinary Tract Infections”, The Connecticut Academy of Physicians
Assistants, Charter Oak Conference, Four Points Hotel, Waterbury, Connecticut,
April 27, 1999.
41
179.
“Prognostic Significant of Topoisomerase II Alpha Overexpression in Transitional
Cell Carcinoma of the Urinary Bladder”, American Urological Association, Dallas,
Texas, May, 1999.
180.
“Antonio Scarpa: Contributions of a Great Surgeon and Anatomist”, American
Urological Association, Dallas, Texas, May, 1999.
181.
“The Diagnosis, and Management of Urethritis, Epididymitis, and Prostatitis”,
Hudson Valley Community College Physician’s Assistant Program, Albany Medical
College, Albany, New York, July 7, 1999.
182.
“Diagnosis and Management of Erectile Dysfunction, Including a Comprehensive
Update on Sildenafil”, Pfizer Upstate New York Representatives Comprehensive
Update Meeting, Albany Medical College, Albany, New York, July 27, 1999.
183.
“Benign Prostatic Hyperplasia: Long-Term Results of a Progressive Condition”,
Department of Medicine, Samuel Stratton VA Medical Center, Albany, New York,
July 29, 1999.
184.
“Extraperitoneal Flank Approach Minimizes Morbidity and Hospitalization for
Radical Nephrectomy”, Albany Medical College Division of Urology Alumni
Reunion, Albany Medical College, Albany, New York, August 6, 1999.
185.
“Treatment of Advanced Prostate Cancer”, The Cancer Center of Albany Med
Monthly Education Forum, Albany Medical College, Albany, New York, September
21, 1999.
186.
“Treatment of Advanced Prostate Cancer”, Update on Pediatric Urology and
Prostate Cancer, The Desmond Hotel, Albany, New York, September 25, 1999.
187.
“The Diagnosis and Management of Benign Prostatic Hyperplasia”, Geriatric
Medical Grand Rounds, Department of Medicine, Samuel Stratton V.A. Medical
Center, Albany, New York, September 30, 1999.
188.
“New Perspectives in Treating Erectile Dysfunction”, TAP Pharmaceuticals New
England and Northeastern United States Teleconference, October 5, 1999.
189.
“Role of External Beam Radiation Therapy in PT3 Prostate Cancer”, The New
England and Northeastern Sections of the American Urological Association Joint
Annual Meeting, Southampton Princess Hotel, Southampton, Bermuda, October
31-November 4, 1999.
190.
“The Accuracy of Predicting Prostate Tumor Location Based on Endo-Rectal Coil
Magnetic Resonance Imaging (MRI): A Correlation of Histopathology with
Imaging and Needle Biopsy”, The New England and Northeastern Sections of the
American Urological Association Joint Annual Meeting, Southampton Princess
Hotel, Southampton, Bermuda, October 31-November 4, 1999.
191.
“The Significance of the Location of Positive Margins after Radical
Prostatectomy”, The New England and Northeastern Sections of the American
Urological Association Joint Annual Meeting, Southampton Princess Hotel,
Southampton, Bermuda, October 31-November 4, 1999.
192.
“Quality of Life Assessment and Urodynamic Findings in Patients Undergoing
Prostatic Cryoablation After Radiation Failiure”, The New England and
42
Northeastern Sections of the American Urological Association Joint Annual
Meeting, Southampton Princess Hotel, Southampton, Bermuda, October 31November 4, 1999.
193.
“The Diagnosis and Management of Benign Prostatic Hyperplasia”, Health
Services Division of the Federal Bureau of Prisons, Clinical Directors Meeting,
San Diego, California, December 7, 1999.
194.
“Erectile Dysfunction in the Cancer Patient”, The Cancer Center of Albany
Medical Center Monthly Education Forum, Albany Medical Center, Albany, New
York, January 18, 2000.
195.
“The Significance of the Location of Positive Margins after Radical
Prostatectomy”, American Urological Association, Atlanta, Georgia, May, 2000.
196.
“Endorectal MRI: Assessment of the Utility for Prostate Cancer Localization”,
American Urological Association, Atlanta, Georgia, May, 2000.
197.
“Role of External Beam Radiation Therapy in pT3 Prostate Cancer”, American
Urological Association, Atlanta, George, May, 2000.
198.
“Epidemiology, Risk Factors, Office Evaluation and New WHO Guidelines for
Erectile Dysfunction”, Male and Female Sexual Dysfunction Update 2000, The
Albany Marriott Hotel, Albany, NY, May 6, 2000.
199.
“Intracavernosal Agents, Intraurethral Agents, Vacuum Therapy and Penile
Prosthetic Devices”, Male and Female Sexual Dysfunction Update 2000, The
Albany Marriott Hotel, Albany, NY, May 6, 2000.
200.
“Prostate Cancer: Advances in Clinical Management”, Upstate Urologic
Surgeons Quarterly Conference, Mirror Lake Inn, Lake Placid, New York, June 2,
2000.
201.
“The Diagnosis and Medical Management of Benign Prostatic Hyperplasia”, The
Urological Association of Wilkes-Barre, Pennsylvania, The Overbrook
Restaurant, Wilkes-Barre, Pennsylvania, July 20, 2000.
202.
“Artificial Urinary Sphincter Placement in Patients Undergoing Prostate
Cryoablation after Failed Radiation Therapy for Prostate Carcinoma”, the
Northeastern Section of the American Urological Association Annual Meeting, the
Westin William Penn Hotel, Pittsburgh, Pennsylvania, September 14-17, 2000.
203.
“Overview of Prostate and Urological Cancers”, The Cancer Center of Albany
Med Monthly Education Forum, Albany Medical College, Albany, New York,
September 19, 2000.
204.
“Treatment of Advanced Prostate Cancer and Update on Current Urologic
Oncology Clinical Trials in the Division of Urology of Albany Medical College”, The
Cancer Center of Albany Med Monthly Education Forum, Albany Medical College,
Albany, New York, September 19, 2000.
205.
“The Dilemma of PSA Recurrence”, Pranzo Ristorante, Buffalo, New York,
September 20, 2000.
206.
“Contemporary Issues in the Management of Sexual Dysfunction”, AAFP
Conference, Community General Hospital, Syracuse, New York, September 29,
43
2000.
207.
“The Dilemma of PSA Recurrence”, Grille 23, Boston, Massachusetts, November
14, 2000.
208.
“The Diagnosis and Management of Benign Prostatic Hyperplasia”, Department
of Medicine, Medical Grand Rounds, Albany Medical College, Albany, New York,
February 16, 2001.
209.
“The Diagnosis and Management of Benign Prostatic Hyperplasia”, Nicole’s
Restaurant, Albany, New York, March 26, 2001.
210.
“Immediate vs. Deferred Hormonal Therapy: Challenging Watchful Waiting”,
Portland Sea Dogs Stadium, Portland, Maine, May 10, 2001.
211.
Giovanni’s II Restaurant, Darian, Connecticut, May 14, 2001.
212.
“The Management of PSA Recurrence”, Kingston Man to Man Prostate Cancer
Support Group, Hurley Reformed Church, Kingston, New York, May 15, 2001.
213.
Recent Advances in Prostate Cancer, The Fairmont Copley Plaza, Boston,
Massachusetts, May 18, 2001.
214.
Urology Grand Rounds, Albany Medical College, Albany, New York, May 24,
2001.
215.
“Immediate v. Deferred Hormonal Therapy: Challenging Watchful Waiting”,
Raffaello’s Restaurant, Hamden, Connecticut, June 11, 2001.
216.
“Immediate v. Deferred Hormonal Therapy: Challenging Watchful Waiting”, The
Empire Restaurant, Providence, Rhode Island, June 19, 2001.
217.
“Prostatitis: Current Management”, The Golf Club at Mansion Ridge, Woodbury,
218.
“Prostatic Chemoablation”, Department of Urology, The Bassett Hospital,
Cooperstown, New York, June 27, 2001.
219.
“Update on Prostate Cancer Screening and Biopsy Techniques”, Recent
Advances in Prostate Cancer, The Ritz-Carlton, Atlanta, Georgia, July 13, 2001.
220.
“Prostate Cancer – Importance of Early Detection and Treatment”, Plattsburgh
Man to Man Prostate Cancer Support Group, Inn at Smithfield, Plattsburgh, NY,
October 18, 2001.
221.
“Prostate Cancer: Early Detection and Therapy”, Medical Grand Rounds,
Champlain Valley Physicians Hospital Medical Center, Plattsburgh, NY, October
19, 2001.
222.
Urology Grand Rounds, Department of Urology at SUNY Upstate Medical
University, Syracuse, New York, November 8, 2001.
44
223.
“The Diagnosis and Management of Benign Prostatic Hyperplasia”, Albany
Medical College Department of Family Practice, Noontime Grand Rounds,
Albany, New York, November 15, 2001.
224.
“Getting into Gear: New Tactics for Men’s Health”, VFW Post #8758, Troy, New
York, November 27, 2001.
225.
“Diagnosis and Management of Erectile Dysfunction, Current State of the Art”,
Department of Medicine, Samuel Stratton VA Medical Center, Albany, New York,
March 6, 2002.
226.
“Adjuvant and Neoadjuvant Hormonal Therapies”, Recent Advances in the
Management of Prostate Cancer, The Ritz Carlton, Cleveland, Ohio, April 5,
2002.
227.
“Benign Prostatic Hyperplasia: New Thoughts on an Old Subject”, Urology Grand
Rounds, Albany Medical College, Albany, New York, April 11, 2002.
228.
“The Diagnosis and Management of Erectile Dysfunction”, AAFP, Community
General Hospital, Syracuse, New York, April 12, 2002.
229.
Advances in the Management of Prostate Cancer, The Park Hyatt, Philadelphia,
Pennsylvania, April 19, 2002.
230.
“Adjuvant and Neoadjuvant Hormonal Therapies”, Recent Advances in the
Management of Prostate Cancer, The Adam’s Mark Hotel, Charlotte, North
Carolina, May 10, 2002.
231.
“Rising PSA: Selection for Early Therapy”, Recent Advances in the Management
of Prostate Cancer, the Adam’s Mark Hotel, Charlotte, North Carolina, May 10,
2002.
232.
“The Current Diagnosis and Management of Benign Prostatic Hyperplasia”, The
Cranwell Resort and Golf Club, Lenox, Massachusetts, June 25, 2002.
233.
“Rising PSA: Selection for Early Therapy”, Recent Advances in the Management
of Prostate Cancer, the Ritz Carlton Hotel, Dearborn, Michigan, July 19, 2002.
234.
“Rising PSA: Selection for Early Therapy”, Upstate Urologic Surgeons Quarterly
Conference, Mirror Lake Inn, Lake Placid, NY, August 2, 2002.
235.
“The Diagnosis and Management of Erectile Dysfunction”, Albany Medical
College Department of Family Practice, Sitar Indian Restaurant, Colonie, New
York, August 13, 2002.
236.
“Management of Biochemical Recurrence Following Definitive Therapy”, Current
Concepts in Men’s Health, The Sagamore Resort, Lake George, Bolton Landing,
New York, August 16, 2002.
237.
“Medical Knowledge Forums in Urology, The Role of DHT in Prostate Health: An
Evolution in Understanding”, Mansion Hill Inn and Restaurant, Albany, New York,
September 5, 2002.
238.
Evolution in Understanding”, Benevento’s Restaurant, Syracuse, New York,
45
September 12, 2002.
239.
Advances in the Management of Prostate Cancer, The New York Roosevelt
Hotel, New York, NY, September 20, 2002.
240.
“Detection of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy:
Effect of Extended Biopsy Schemes”, The Northeastern Section of the Americal
Urological Association Annual Meeting, Fairmont Tremblant Hotel, MontTremblant, Quebec, Canada, September 26-29, 2002.
241.
“Coaguloop and Wedge Loop Offers Safe and Efficacious Outpatient TURP”,
The Northeastern Section of the American Urological Association Annual
Meeting, Fairmont Tremblant Hotel, Mont-Tremblant, Quebec, Canada,
September 26-29, 2002.
242.
“Initial Experience with Hand Assisted Laparoscopic Nephrectomy”, The
Northeastern Section of the American Urological Association Annual Meeting,
Fairmont Tremblant Hotel, Mont-Tremblant, Quebec, Canada, September 26-29,
2002.
243.
Evolution in Understanding", Park Lane Restaurant, Buffalo, New York, October
2, 2002.
244.
“Benign Prostatic Hyperplasia: Current Status of Medical Management”,
Department of Medicine, Medical Grand Rounds, Albany Medical Center, Albany,
New York, October 25, 2002.
245.
“Medical Knowledge Forums in Urology, Signs, Symptoms and Care:
Understanding the Role of PSA as a Marker for BPH”, Yono’s Restaurant,
Albany, New York, November 7, 2002.
246.
Understanding the Role of PSA as a Marker for BPH”, Oliver’s Restaurant,
Buffalo, New York, November 13, 2002.
247.
Understanding the Role of PSA as a Marker for BPH”, P.J. Dorsey’s Restaurant,
Syracuse, New York, November 26, 2002.
248.
“Management of Biochemical Recurrence Following Definitive Therapy”, The
Urological Association of the Mohawk Valley Monthly Grand Rounds, O’Connors
Alexander Hamilton Inn, Clinton, New York, December 4, 2002.
249.
“Benign Prostatic Hyperplasia: Current Status of Medical Management”,
Carmine’s Restaurant, Albany, New York, December 5, 2002.
250.
“Advancements in Benign Prostatic Hyperplasia Therapy”, Hudson Valley Area
Urologic Society, Ship’s Lantern Inn, Milton, New York, December 19, 2002.
251.
Understanding the Role of PSA as a Marker for BPH”, Crystal Barn, Pittsford,
New York, January 14, 2003.
252.
“The Evolving Role of Dihydrotesterone (DHT) in Prostate Health and Disease”,
46
Albany Medical Center Internal Medicine Group Noontime Grand Rounds,
Pinnacle Place, Albany, New York, January 21, 2003.
254.
”Advancements in Benign Prostatic Hyperplasia Therapy”, Nyack Urologic Society,
Lanterna Tuscan Bistro, Nyack, New York, January 23, 2003
253.
“Benign Prostatic Hyperplasia: Management of Disease Progression”, Urology
Grand Rounds, Albany Medical College, Albany, New York, January 30, 2003.
254.
“Benign Prostatic Hyperplasia: Management of Disease Progression”,
Plattsburgh Urologic Society, Anthony’s Restaurant, Plattsburgh, New York,
January 30, 2003.
255.
“Critical Assessment of Hand Assisted Laparoscopic Nephrectomy (HALN) by
the Non-Laparoscopist: Initial Outcomes and Learning Curve”, Maine Urological
Association Winter Meeting 2003, The Grand Summit Resort Hotel, Carrabassett
Valley, Sugar Loaf, USA, February 8, 2003.
256.
“An Update on Erectile Dysfunction”, Lanzi’s on the Lake, Mayfield, New York,
February 27, 2003.
257.
“Diagnosis and Treatment of Benign Prostatic Hyperplasia”, Maverick Family
Health, Blue Mountain Bistro, Woodstock, New York, March 6, 2003.
258.
“Advancements in Benign Prostatic Hyperplasia Treatment”, Westchester Area
Urologists, Crabtree’s Kittle House, Chappaqua, New York, March 11, 2003.
259.
“Diagnosis and Treatment of Benign Prostatic Hyperplasia”, Lynn Community
Health Center Grand Rounds, Lynn Community Health Center, Lynn,
Massachusetts, March 12, 2003.
260.
“Diagnosis and Treatment of Benign Prostatic Hyperplasia”, North Shore Medical
Providers, Yanks Restaurant, Beverly Farms, Massachusetts, March 12, 2003.
261.
“Advancements in Benign Prostatic Hyperplasia Therapy”, Buffalo South Territory
Urologists, Fox Valley Country Club, Lancaster, New York, April 2, 2003.
262.
“Advancements in Benign Prostatic Hyperplasia Treatment”, Rochester Area
Urologists, Max of Eastman Place, Rochester, New York, April 8, 2003.
263.
“The Efficacy and Tolerability of Dutasteride”, Burlington Vermont Area
Urologists, New England Culinary Institute at the Inn at Essex, Essex, Vermont,
April 18, 2003.
264.
“Prognostic Value of High Grade Prostatic Intraepithelial Neoplasia and Atypia in
the Extended Prostate Biopsy Era”, American Urological Association, Chicago,
Illinois, April 27, 2003.
265.
“Plenary Session IV Highlights from Tuesday, April 29, 2003, Benign Prostatic
Hyperplasia, American Urological Association, Chicago, Illinois, April 30, 2003.
266.
“Long Term, Evidence Based Management of BPH”, Urologists Attending AUA
Meeting, Catch 35, Chicago, Illinois, April 27, 2003.
267.
“Current Trends in Detection and Treatment of BPH”, Milton, New York Area
Urologists, Ship’s Lantern Inn, Milton, New York, May 13, 2003.
47
268.
“Diagnosis and Management of Erectile Dysfunction”, Albany Medical College
Family Practice Residents, Carmine’s Restaurant, Albany, New York, May 15,
2003.
269.
“Current Trends in Detection and Treatment of BPH”, Croton Falls Area
Physicians, Finch Tavern, Croton Falls, New York, May 28, 2003.
270.
“Primary Care Perspectives on Erectile Dysfunction”, Male Sexual Health:
Practical Clinical Solutions CME Symposium, Renaissance Dallas North, Dallas,
Texas, May 31, 2003.
271.
“Current Trends in Detection and Treatment of BPH”, Rutland, Vermont Area
Urologists, Fair Haven Inn, Fair Haven, Vermont, June 3, 2003
273. “Current Trends in Detection and Treatment of BPH”, Plattsburgh, New York Area
Urologists, Anthony’s Restaurant and Bistro, Plattsburgh, New York, June 6, 2003.
272.
“Update on Prostate Cancer Screening, Detection and Biopsy Techniques”,
Recent Advances in the Management of Prostate Cancer, The Ritz Carlton
Dearborn, Dearborn, Michigan, June 20, 2003
273.
“Diagnosis and Management of Benign Prostatic Hyperplasia”, Westchester
Area Urologists, Crabtree Kittle House, Chappaqua, New York, June 24, 2003.
274.
“Current Trends in Detection and Treatment of BPH”, Newburgh, New York
Primary Care Practitioners, Cosimo’s on Union, Newburgh, New York, June 26,
2003.
275.
“Current Management of Rising PSA”, Rochester, New York Area Urologists, Rio
Bamba, Rochester, New York, July 22, 2003.
276.
“Update on Prostate Cancer Screening, Detection, and Biopsy Techniques”,
Recent Advances in the Management of Prostate Cancer, The Four Seasons
Hotel, Washington, DC, August 1, 2003.
277.
“Current Management of Rising PSA”, North Country Area Urologists, Mirror
Lake Inn, Lake Placid, New York, August 8, 2003.
278.
“BPH: Management of Disease Progression”, Current Concepts in Men’s Health
2003, The Sagamore Resort, Lake George, Bolton Landing, New York, August
17, 2003.
279.
“Prognostic Value of High Grade Prostatic Intraepithelial Neoplasia and Atypia in
the Extended Prostate Biopsy Era”, The Northeastern Section of the American
Urological Association, Halifax, Nova Scotia, Canada, September 5, 2003.
280.
“Upper Tract Transitional Cell Carcinoma”, Outcomes of Ureteroscopic and
Percutaneous Approach”, the Northeastern Section of the American Urological
Association, Halifax, Nova Scotia, Canada, September 5, 2003.
281.
“Critical Assessment of Hand Assisted Laparoscopic Nephrectomy (HALN) by
the Non-Fellowship Trained Laparoscopist: Initial Outcomes in Learning Curve”,
The Northeastern Section of the American Urological Association, Halifax, Nova
Scotia, Canada, September 5, 2003.
48
282.
“The Diagnosis and Management of Benign Prostatic Hyperplasia”, Prime
Medical Associates of Hudson, Kozels’ Restaurant, Ghent, New York, September
10, 2003.
283.
“Current Trends in the Management of Benign Prostatic Conditions: A CME
Dinner Series”, The Century House, Latham, New York, September 16, 2003.
284.
“The Current State of the Medical Management of Erectile Dysfunction”, Upstate
Pfizer Sales Representatives, The Crown Plaza Hotel, Albany, New York,
September 24, 2003.
285.
“Current Management of Benign Prostatic Hyperplasia”, Plattsburgh, New York
Area Urologists and Primary Care Practitioners, Anthony’s Restaurant,
Plattsburgh, New York, November 21, 2003.
286.
“Current Diagnosis and Management of Benign Prostatic Hyperplasia”, Suffern
Area Primary Care Practitioners, Pasta Cucina, Suffern, New York, November
24, 2003.
287.
“Male Sexual Circuitry: Sexual Dysfunction and Rapid Ejaculation”, Sexual Health
Hospital Symposia, Half Day CME Program, The Desmond Hotel and
Conference Center, Albany, New York, January 17, 2004.
288.
“Current Management of Bone Complications in Prostate Cancer”, Division of
Urology Research Conference, Albany, New York, February 2, 2004.
289.
“Primary Care Perspectives on Erectile Dysfunction”, Grand Rounds, Department
of Family Practice, Albany Medical College, Albany, New York, February 5, 2004.
290.
“Benign Prostatic Hyperplasia and Medical Treatment Options”, Upstate SanofiSynthelabo Sales Reprentatives, The Marriott Hotel, Albany, New York, February
24, 2004.
291.
“Benign Prostatic Hyperplasia 2004”, Syracuse VA Hospital Nurse Practitioners
Association Monthly Meeting, Avad Evans Restaurant, Syracuse, New York,
February 26, 2004.
292.
“BPH and Medical Treatment Options”, Sign of the Tree Lo Portos Restaurant,
Albany, New York, March 24, 2004.
293.
“Benign Prostatic Hyperplasia, the Role of DHT”, North Country Medical Group,
Champlain, New York, March 25, 2004.
294.
“Management of Erectile Dysfunction”, Anthony’s Restaurant, Plattsburgh, New
York, March 25, 2004.
295.
“Hand Assisted Laparoscopic Nephrectomy (HALN)”, Community Care
Physicians, P.C. Medical Education Dinner Series, Capital Region Health Park,
Latham, New York, March 30, 2004.
296.
“Optimal Integration of Hormone Therapy and Chemotherapy in Men with
Biochemical Failure D1.5”, Recent Advances in the Management of Prostate
Cancer, The Ritz Carlton Chicago, Chicago, Illinois, April 2, 2004.
297.
“Complications of Treatment of Advanced Prostate Cancer”, Recent Advances
in the Management of Prostate Cancer, The Ritz Carlton Chicago, Chicago, IL,
49
April 2, 2004.
298.
“Optimal Integration of Hormone Therapy and Chemotherapy in Men with
Biochemical Failure, D1.5”, Urology Grand Rounds, Albany Medical College,
299.
“Complications of Treatment of Advanced Prostate Cancer”, Recent Advances in
the Management of Prostate Cancer, W Atlanta Hotel, Atlanta, Georgia, April 16,
2004.
300.
“The Changing Landscape in the Treatment of Erectile Dysfunction”, Lo Porto at
the Sign of the Tree, Empire State Plaza, Albany, New York, April 20, 2004.
301.
“The Role of DHT in the Management of Benign Prostatic Hyperplasia”, The
Desmond Hotel and Conference Center, Albany, New York, May 4, 2004.
302.
“Advances in the Management of Progressive BPH: Dual Inhibition of 5 AlphaReductase”, Kirker’s Steak and Seafood, Latham, New York, June 22, 2004.
303.
“Complications of Treatment of Advanced Prostate Cancer”, Recent Advances in
the Management of Prostate Cancer, The Pierre, New York, New York, July 9,
2004.
304.
“Update on Medical Management of Erectile Dysfunction”, Current Concepts in
Men’s Health 2004, The Sagamore Resort Lake George, Bolton Landing, New
305.
“Current Management of Benign Prostatic Hyperplasia”, Nicole’s Bistro, Albany,
New York, September 30, 2004.
306.
“A Retrospective Analysis of Pyeloplasty in New York State: a 19 Year Review”,
The Northeastern Section of the American Urological Association Annual
Meeting, Westin Savannah Harbor Resort, Savannah, Georgia, October 29,
2004.
307.
“Percent Free Prostate Specific Antigen in the Extended Biopsy Era: Still
Relevent?”, The Northeastern Section of the American Urological Association
Annual Meeting, Westin Savannah Harbor Resort, Savannah, Georgia, October
30, 2004.
308.
“Tolerability and Efficacy of Bicalutamide Monotherapy in Biochemical
Recurrence of Prostate Cancer”, The Northeastern Section of the American
Urological Association Annual Meeting, Westin Savannah Harbor Resort,
Savannah, Georgia, October 30, 2004.
309.
“Advances in the Management of Progressive BPH: Dual Inhibition of 5 AlphaReductase” Yono’s Restaurant, Albany, New York, November 4, 2004.
310.
“Selected Options in the Treatment of BPH”, Lemon Grass Restaurant,
Syracuse, New York, November 17, 2004.
311.
“Current Management of Benign Prostatic Hyperplasia”, The Bulls Head Inn,
Campbell Hall, New York, December 15, 2004.
312.
“Current Management of Benign Prostatic Hyperplasia”, Valkin Restaurant,
Valatie, New York, January 25, 2005.
50
313.
“Treating BPH in the VA”, Medical Grand Rounds, Bath Veteran’s Administration
Hospital, Bath, New York, January 28, 2005.
314.
“Benign Prostatic Hyperplasia: New Concepts in Medical Management” Men’s
Health for the Primary Care Provider: Skills You Can Use, The Desmond Hotel,
Albany, New York, February 12, 2005.
315.
“Treating BPH in the VA”, Medical Grand Rounds, Syracuse Veteran’s
Administration Hospital, Syracuse, New York, February 15, 2005.
316.
“Long Term, Evidence-Based Management of BPH”, Century House, Albany,
New York, February 15, 2005.
317.
“Primary Care Perspectives on Erectile Dysfunction” Community Care
Physicians, Schodack, New York, March 10, 2005.
318.
“Benign Prostatic Hyperplasia: Management of Disease Progression” Legal Sea
Foods, Westchester, New York, March 23, 2005.
319.
“Advances in the Management of Progressive BPH: Dual Inhibition of 5 AlphaReductase” Café Capriccio, Albany, New York, March 31, 2005.
320.
“Biochemical Failure: Selection for Early Therapy” 2005 Prostate Cancer Update,
InterContinental Hotel, San Juan, Puerto Rico, April 9, 2005.
321.
“Complications of Treatment of Advanced Prostate Cancer” 2005 Prostate
Cancer Update, InterContinental Hotel, San Juan, Puerto Rico, April 9, 2005.
322.
“Diagnosis and Management of Benign Prostatic Hyperplasia”, The Otesago
Hotel, Cooperstown, New York, April 28, 2005.
323.
“Benign Prostatic Hyperplasia: Management of Disease Progression”,
Department of Surgery Grand Rounds, Albany Medical College, Albany, New
York, May 5, 2005.
324.
“Benign Prostatic Hyperplasia: Management of Disease Progression”, Anthony’s
Restaurant, Plattsburgh, New York, May 12, 2005.
325.
“Benign Prostatic Hyperplasia: Management of Disease Progression” Arad
Evans Inn, Fayetteville, New York, June 14, 2005.
326.
“Benign Prostatic Hyperplasia: Management of Disease Progression” Community
Care Physicians, Schodack, New York, June 16, 2005.
327.
“Benign Prostatic Hyperplasia: Management of Disease Progression” Elmira
Urological Associates, Elmira, New York, June 28, 2005.
328.
“Diagnosis and Management of Benign Prostatic Hyperplasia”, The Rodizio
Churascaria at the Turning Stone, Verona, New York, June 28, 2005.
329.
“New Concepts in Screening and Prevention of Prostate Cancer”, Recent
Advances in the Management of Prostate Cancer, Grand Hyatt New York, New
York, New York, July 29, 2005.
330.
“Benign Prostatic Hyperplasia: Management of Disease Progression”, Current
51
Concepts in Men’s Health, The Sagamore Resort Lake George, Bolton Landing,
New York, August 13, 2005.
331.
“Diagnosis and Management of Benign Prostatic Hyperplasia”, Albany Medical
College Family Practice Grand Rounds, Albany Medical College, Albany, New
332.
“Management of Erectile Dysfunction”, Capitol Region Health Care, Rensselear,
New York, September 1, 2005.
333.
“Diagnosis and Management of Benign Prostatic Hyperplasia”, Angelo’s 667
Prime, Albany, New York, September 15, 2005.
334.
“Treatment Strategies: A Practical Approach to Managing Enlarged Prostate
(EP)”, Carmine’s Restaurant, Albany, New York, October 6, 2005.
335.
“Diagnosis and Management of Benign Prostatic Hyperplasia”, Fair Haven Inn,
Fair Haven, Vermont, October 20, 2005.
336.
“Clinical Correlation Between Erectile Dysfunction and Lower Urinary Tract
Symptoms”, El Mariachi Restaurant, Albany, New York, October 25, 2005.
337.
“A Cost-Effective Protocol In Obtaining Site-Specific Prognostic Information For
Extended Prostate Biopsy”, Northeastern & New England Sections of the
American Urological Association Joint Annual Meeting, Fairmont Southampton,
Bermuda, November 3, 2005.
338.
“Urologic Technology Update: Robotic Laparoscopic Radical Prostatectomy and
Prolieve Thermodilation Microwave Therapy”, Seventh Annual Fall Educational
Forum: “The Technology of Tomorrow in the Healthcare of Today”, Capital
Region Health Park, Latham, New York, November 16, 2005.
339.
“Medical Therapy for Overactive Bladder”, Community Care Physicians, P.C.
Medical Education Dinner Series :“Overactive Bladder Community Symposium
2006”, Capital Region Health Park, Latham, New York, April 4, 2006.
340.
“Current Management of Benign Prostatic Hyperplasia”, The Otesago Hotel,
Cooperstown, New York, April 5, 2006.
341.
“A.I.M. Advances in Men’s Health. Treatment Strategies: A Practical Approach to
Managing Enlarged Prostate (EP)”, Capital Region Nurse Practioners’ Society,
Lombardo’s Restaurant, Albany, New York, April 25, 2006.
342.
“Overactive Bladder: Medical Therapy” Grand Rounds, Albany Medical Center
Family Practice , Albany, New York, May 25, 2006.
343.
“Update on Robotic Prostatectomy: Is It Better Than Open Prostatectomy?” 2006
Prostate Cancer Review: Redefining Disease Management, The Westin
Southfield Detroit, Southfield, Michigan, July 28, 2006.
344.
“The Link Between Erectile Dysfunction (ED) and Comorbid Conditions”,
Chameleon On The Lake, Saratoga Springs, New York, July 31, 2006.
345.
“Point-Counterpoint: Management of LUTS, Minimally Invasive Therapy is Best”
Current Concepts in Men’s Health 2006, The Sagamore Resort, Lake George,
Bolton Landing, New York, August 11, 2006.
52
346.
“Bicalutamide Monotherapy for Biochemical Recurrence of Prostate Cancer”,
American Urological Association Northeastern Section 2006 Annual Meeting,
Ottawa, Canada, September 8, 2006.
347.
“Short-term Independent Outcomes with the Prolieve Thermodilation System for
BPH”, American Urological Association Northeastern Section 2006 Annual
Meeting, Ottawa, Canada, September 8, 2006.
348.
(EP)”, Yono’s Restaurant, Albany, NY, September 12, 2006.
349.
“The Medical Management of BPH Symptoms”, Mid-Hudson Family Practice
Residency Program Grand Rounds, Kingston Hospital, Kingston, New York,
September 28, 2006.
350.
(EP)”, Scotia Glenville Family Practice, Ballston Lake, NY, November 1, 2006.
351.
“What’s Going On With Me? Helping You Understand Your Bladder”, Overactive
Bladder Symposium 2006, Community Care Physicians, P.C. Medical Education
Dinner Series, Capital Region Health Park, Latham, NY, November 16, 2006
352.
“The Only Dual 5 ARI for the Treatment of Enlarged Prostate (EP), Managing
Enlarged Prostate with Dutasteride”, Scotia Glenville Family Practice, Ballston
Lake, NY, June 6, 2007.
353.
“Identifying and Managing Men with Enlarged Prostate (EP): Targeting Symptoms
at Their Source”, Albany Medical Center Family Practice Residency Program
Grand Rounds, Albany Medical Center Family Practice, Albany, NY, June 7,
2007.
354.
(EP)”, El Mariachi’s , Albany, NY, July, 24, 2007.
355.
“The Medical Management of BPH Symptoms”, Monteverde at Oldstone Manor,
Cortlandt Manor, NY, July 25, 2007.
356.
“Treating the Male Overactive Bladder Patient”, Elda’s On Lark, Albany, NY,
August 15, 2007.
357.
“Treating Enlarged Prostate (EP): A Urologist’s Perspective”, Iris’s Café,
Plattsburgh, NY, August 30, 2007.
358.
“Outcomes with the Prolieve Thermodilation System for BPH”, American
Urological Association Northeastern Section 2007 Annual Meeting, Rochester,
NY, September 7, 2007.
359.
“Androgen Replacement Therapy After Prostate Cancer”, American Urological
Association Northeastern Section 2007 Annual Meeting, Rochester, NY,
September 9, 2007.
360.
“Treating the Male Overactive Bladder Patient”, 677 Prime, Albany, NY,
November 15, 2007.
361.
“Androgen Replacement Therapy After Prostate Cancer” Sexual Medicine
Society of North America 2007 Winter Scientific Meeting, Westin Chicago River
53
North, Chicago, IL, December 7, 2007.
362.
“(TESA) Tolteradine Efficacy in OAB in Sexually Active Women”, Carmine’s
Restaurant, Albany, NY, February 13, 2008.
363.
“The Medical Management of BPH Symptoms”, Community Care Physicians,
Castleton, NY, April 24, 2008.
364.
“Treating The Male Overactive Bladder Patient”, Chez Sophie Bistro, Saratoga
Springs, NY, May 8, 2008.
365.
“Use of Anticholinergic Therapy in Men”, Current Concepts in Men’s Health 2006,
The Sagamore Resort, Lake George, Bolton Landing, New York, August 8, 2008.
366.
“Gleason Grade at the Surgical Margin: Correlation with Primary Gleason Grade
and Recurrence”, The American Urological Association Northeastern Section
2008 Annual Meeting, Hyatt Regency Tamaya Resort & Spa, Santa Ana Pueblo,
NM, September 18, 2008.
367.
“Role of Biopsy in the Management of Small Renal Masses”, The American
Urological Association Northeastern Section 2008 Annual Meeting, Hyatt
Regency Tamaya Resort & Spa, Santa Ana Pueblo, NM, September 18, 2008.
368.
“Combination Medical Therapy for Lower Urinary Tract Symptoms in Men”, 41st
Annual Duke Urologic Assembly, Four Seasons Hotel, Las Vegas, Nevada,
March 9, 2009.
369.
“Coding and Reimbursement Update 2009” 41st Annual Duke Urologic Assembly,
Four Seasons Hotel, Las Vegas, Nevada, March 10, 2009.
370.
“Role of Biopsy in the Management of Small Renal Masses”, American Urological
Association Annual Meeting, Chicago, IL, April 27, 2009.
371.
“How a CPT code is developed and the Importance of AUA members in the
reimbursement process” Coding and Reimbursement Update 2009, American
Urological Association Annual Meeting, Chicago, Illinois, April 27, 2009.
372.
“Daily PDE-5 Inhibition Therapy, Does It Make Sense?” Current Concepts in
Men’s Health 2009, The Sagamore Resort, Lake George, Bolton Landing, New
York, August 14, 2009
373.
“Comparison of Tertiary Center and Referred Prostate Biopsies: Impact of ReReview on Gleason Score Accuracy” The Northeastern Section of the American
Urological Association Annual Meeting, Fairmont The Queen Elizabeth Hotel,
Montreal, Quebec, Canada, October 7-11, 2009.
374.
“Toremifene 80 mg Phase 3 Trial in Men on ADT Demonstrates Improvement in
Gynecomastia Compared to Placebo” The Northeastern Section of the American
Urological Association Annual Meeting, Fairmont The Queen Elizabeth Hotel,
Montreal, Quebec, Canada, October 7-11, 2009.
375.
“Role of Biopsy in the Management of Small Renal Masses” The Northeastern
Section of the American Urological Association Annual Meeting, Fairmont The
Queen Elizabeth Hotel, Montreal, Quebec, Canada, October 7-11, 2009.
376.
“The Diagnosis and Management of Prostatitis and Urethritis” Physician’s
54
Assistant Lecture Series,
10, 2010.
Albany Medical College, Albany, New York, March
377.
“Health Reform and the AUA” 42nd Annual Duke Urologic Assembly, Disney’s
Grand Floridian Resort & Spa, Lake Buena Vista, Florida, March 25, 2010
378.
“ Coding & Reimbursement” 42nd Annual Duke Urologic Assembly, Disney’s
Grand Floridian Resort & Spa, Lake Buena Vista, Florida, March 25, 2010
379.
“Health Policy Update, U.S. Perspective” The Northeastern Section of the
American Urological Association Annual Meeting, The Westin Convention Center
Hotel, Pittsburgh, PA, September 22-26, 2010
380.
“Percutaneous Ablation of Renal Masses: The Albany Medical Center
Experience” The Northeastern Section of the American Urological Association
Annual Meeting, The Westin Convention Center Hotel, Pittsburgh, PA, September
22-26, 2010
381.
“Toremifene 80 mg Demonstrates Reduction in Fracture Risk in Men Who are
Less than 80 Years of Age on Androgen Deprivation Therapy.” The
The Westin Convention Center Hotel, Pittsburgh, PA, September 22-26, 2010
382.
“Quality of Cystectomy Care and Partnerships with Payers” Bladder Cancer
Think Tank 2011, Lowes Coronado Bay, Coronado, CA, August 6, 2011
383.
“Coding and Reimbursement Update For Urologists ”, Current Concepts in
Men’s Health 2011, The Sagamore, Lake George, Bolton Landing, New York,
August 12, 2011.
384.
“Update on Tissue Ablative Technologies for Benign Prostatic Hyperplasia”
Current Concepts in Men’s Health 2011, The Sagamore , Lake George, Bolton
Landing, New York, August 12, 2011
385.
“Smaller Tumor Size is a Risk Factor for Positive Margins in Partial
Nephrectomy.” The Northeastern Section of the American Urological Association
63rd Annual Meeting, Roosevelt Hotel, New Orleans, LA, October 26-30, 2011
386.
“Best of Posters, Moderated Poster Session I: Oncology 1”, The Northeastern
Section of the American Urological Association Annual Meeting, Roosevelt Hotel,
New Orleans, LA, October 27, 2011.
MEETINGS ATTENDED:
1.
Hoechst Marion Roussel Nilandron Investigators Meeting, Cancun, Mexico.
January 10-12, 1997.
2.
Schering Prostate Cancer Speakers Bureau and Investigators Meeting. January
30-February 2, 1997.
3.
American Urological Association Meeting, 1997.
4.
Zeneca Pharmaceuticals Prostate Cancer Investigators Meeting, The Royal York
Hotel, Toronto, Canada, July 25-26, 1997.
5.
"Expert to Expert" Meeting, The Visiting Professor Program in Urology, Flomax
55
(Tamsulosin), Chicago, Illinois, August 22-23, 1997.
6.
The Holmium Laser in Urology, Montreal, Quebec, Canada, September 12, 1997.
7.
Eulexin (Flutamide) Speaker Update Meeting, New York, New York, September 13,
1997.
8.
Merck Regional Consultants Meeting for Urology, "The Management of the Adult
Male with Lower Urinary Tract Symptoms: What's New and Where are We Going",
Hyatt Regency Hilton Head, Hilton Head, So. Carolina, October 3-5, 1997.
9.
American College of Surgeons 83rd Annual Clinical Congress, Chicago, Illinois,
October 15-16, 1997.
10.
Society of University Urologists Annual Meeting, Chicago, Illinois, October 16-17,
1997.
11.
Zeneca Prostate Cancer Speakers Update Meeting, Orlando, Florida, January 2225, 1998.
12.
Upstate New York Urological Association's 3rd Annual Residents' Day Competition,
The Sherwood Inn, Skaneateles, New York, April 4, 1998.
13.
Zeneca Pharmaceuticals Clinical Investigators Meeting, "Casodex as Second Line
Therapy for Patients with Advanced Prostate Cancer", Tucson, Arizona, May 1-3,
1998.
14.
American Urological Association Meeting, 1998.
15.
National Visiting Professor Academy Symposium on Quality of Life Issues in
Prostate Cancer Management, Cancun, Mexico, September 24-27, 1998.
16.
Northeastern Section, American Urological Association, Toronto, Ontario, Canada,
October 18-21, 1998.
17.
Prostate Cancer Lecture Series Speakers Update Meeting, Dana Point, California,
January 28-31, 1999.
18.
15th Annual Clinical Update in Obstetrics and Gynecology, Stratton Mountain Inn,
Stratton Mountain,
Vermont, February 9-12, 1999.
19.
Erectile Dysfunction and Benign Prostatic Hyperplasia (BPH): Current Diagnosis
and Management, Hilton Garden Inn, Albany Airport, Albany, New York, April 10,
1999.
20.
Contemporary Issues in the Management of Sexual Dysfunction: A Speaker’s
Training Workshop, Sheraton El Conquistador Resort and Country Club, Tucson,
Arizona, April 17, 1999.
21.
Zeneca Investigator Update Meeting, Dallas, Texas, April 30, 1999.
22.
Viagra (Sildenafil Citrate) Investigator Update Meeting, Hotel Adolphus, Dallas,
Texas, May 1, 1999.
23.
American Urological Association Meeting, Dallas, Texas, May 1-6, 1999.
56
24.
Urofocus Consultants Advisory Board, The Fairmont Copley Plaza, Boston,
Massachusetts, July 16-18, 1999.
25.
American College of Surgeons 85th Annual Clinical Congress, San Francisco,
California, October 10-15, 1999.
26.
Merck 1999 Urology Consultants Meeting, West Point, Pennsylvania, October 22,
1999.
27.
Merck Urology Consultants Meeting, Phoenix, Arizona, February 26, 2000.
28.
Society of University Urologists Annual Meeting, Atlanta, Georgia, April 28, 2000.
29.
Viagra (Sildenafil Citrate) Investigator Update Meeting, Atlanta, Georgia, April 29,
2000.
30.
American Urological Association Meeting, Atlanta, Georgia, April 29-May 4, 2000.
31.
Current Management of ED: Expert Workshop, Rio Grande, Puerto Rico, July 1416, 2000.
32.
Merck Training Consultants Program Seminar, Le Centre Sheraton, Montreal,
Quebec, Canada, August 22, 2000.
33.
American Medical Systems (AMS) Investigators Meeting for Study: Evaluation of the
Safety and Tolerability of Transurethral Dehydrated Alcohol Injection for the
Treatment of Benign Prostatic Hyperplasia. Four Points Hotel, Chicago O’Hare,
Schiller Park, Illinois, October 2, 2000.
34.
Merck 2000 Regional Urology Consultants Meeting, The Millennium Broadway
Hotal, New York, New York, October 27-29, 2000.
35.
Viadur Workshop and Advisory Board, The Omni Berkshire Place, New York, New
York, November 17, 2000.
36.
Hand Assisted Laparoscopic Renal Surgery, Radical Nephrectomy, Donor
Nephrectomy, and Nephroureterectomy Course, Hartford Hospital, Hartford,
Connecticut, December 7, 2000.
37.
“Recent Advances in Prostate Cancer – Faculty Update 2001”, Four Seasons, Las
Vegas, Nevada, January 5, 2001.
38.
“Casodex Early Prostate Cancer Program Investigator Meeting”, Disney’s
Contemporary Resort, Orlando, Florida, January 19-21, 2001
39.
“Amgen Praecis Prostate Cancer Regional Advisory Board Meeting”, Park City,
Utah, February 7-8, 2001.
40.
“2001 National Urology Consultants Meeting”, The Peabody Orlando, Orlando,
Florida, March 23-25, 2001.
41.
“Recent Advances in Prostate Cancer,” The Fairmont Copley Plaza, Boston,
Massachusetts, May 18, 2001.
42.
“Recent Advances in Prostate Cancer,” The Ritz-Carlton, Atlanta, Georgia, July 13,
57
2001.
43.
“Controversies in Men’s Health”, The Sagamore Resort, Lake George, Bolton
Landing, New York, August 10-12, 2001.
44.
“Faculty Orientation Meeting for the Educational Initiative on Erectile Function
(EIEF)”, The Four Seasons Hotel, Atlanta, Georgia, October 19-21, 2001.
45.
“Recent Advances in the Management of Prostate Cancer – Faculty Update 2002”,
The Four Seasons Hotel, Las Vegas, Nevada, January 4, 2002.
46.
“Boehringer Ingelheim BPH Regional Speaker Meeting”, the Fairmont Hotel, Dallas,
Texas, January 18-19, 2002.
47.
“Hand Assisted Laparoscopic Renal Surgery”, Hartford Hospital, Hartford,
Connecticut, January 23, 2002.
48.
“Regional ED Expert Advisory Panel Meeting”, Rihga Royal Hotel, New York, New
York, March 8-9, 2002.
49.
“Recent Advances in the Management of Prostate Cancer”, The Ritz Carlton,
Cleveland, Ohio, April 5, 2002.
50.
“Recent Advances in the Management of Prostate Cancer”, The Park Hyatt,
Philadelphia, Pennsylvania, April 19, 2002.
51.
“Upstate New York Urological Association’s Annual Resident’s Day Competition”,
the Sherwood Inn, Skaneateles, New York, April 20, 2002.
52.
“Recent Advances in the Management of Prostate Cancer”, The Adam’s Mark
Hotel, Charlotte, North Carolina, May 10, 2002.
53.
“American Urological Association Meeting”, Orlando, Florida, May 25-29, 2002.
54.
“Society of Urologic Oncology Spring Meeting”, Orlando, Florida, May 25, 2002.
55.
“Recent Advances in the Management of Prostate Cancer”, The Ritz Carlton Hotel,
Dearborn, Michigan, July 19, 2002.
56.
“Vardenafil Faculty Update Meeting”, The Grand Hyatt Washington, Washington,
DC, July 19-21, 2002.
57.
“Current Concepts in Men’s Health”, The Sagamore Resort, Lake George, Bolton
58.
“Recent Advances in the Management of Prostate Cancer”, The New York
Roosevelt Hotel, New York, New York, September 20, 2002.
59.
“AVODART (Dutasteride) National Speaker Training Meeting, Sheraton Bal
Harbour, Bal Harbour (Miami), Florida, November 8-9, 2002
60.
“Recent Advances in the Management of Prostate Cancer: Faculty Update 2003”,
The Four Seasons Hotal, Las Vegas, Nevada, January 9-11, 2003.
58
61.
“Maine Urological Association Winter Meeting 2003”, Sugar Loaf, USA, February 12, 2003.
62.
“Pfizer Northeast Regional Advisory Board Meeting”, St. Regis Hotel, New York,
NY, March 28-29, 2003.
63.
“Male Sexual Health: Practical Clinical Solutions Faculty Development Meeting”,
Sofitel Chicago Water Tower Hotel, Chicago, Illinios, April 11-13, 2003.
64.
“American Urological Association Meeting”, Chicago, Illinois, April 26-May 1, 2003.
65.
“Prostate Cancer Update Working Group Meeting”, Millennium Broadway Hotel,
New York, New York, May 14, 2003
66.
“Recent Advances in the Management of Prostate Cancer”, The Ritz Carlton
Dearborn, Dearborn, Michigan, June 20, 2003.
67.
“Recent Advances in the Management of Prostate Cancer”, The Four Seasons
Hotel, Washington, DC, August 1, 2003.
68.
“Current Concepts in Men’s Health”, The Sagamore Resort, Lake George, Bolton
69.
“The Management of Bone Complications Related to Prostate Cancer: Consultants
Meeting”, Essex House, New York, New York, September 5-7, 2003.
70.
“Hot Topics in BPH, Uroxatral Speakers Training Meeting”, The Wyndham Anatole
Hotel, Dallas, Texas, October 24-26, 2003.
71.
“BPH and Beyond: Key Opinion Leaders Scientific Session”, The Waldorf-Astoria,
New York, New York, October 29, 2003.
72.
“New York State Urological Society Executive Committee Meeting”, LaGuardia
Marriott, New York, New York, November 22, 2003.
73.
“Urologic Oncology, Extraordinary Opportunities for Discovery”, Natcher
Conference Center National Institutes of Health, Bethesda, Maryland, December 56, 2003.
74.
“Cialis Speaker Training Meeting”, Gaylord Palms Hotel, Orlando, Florida, January
9-10, 2004.
75.
“Recent Advances in the Management of Prostate Cancer”, The Ritz Carlton
Chicago, Chicago, Illinois, April 2, 2004.
76.
“Recent Advances in the Management of Prostate Cancer”, W Atlanta Hotel,
Atlanta, GA, April 16, 2004.
77.
“American Urological Association Meeting”, San Francisco, California, May 8-13,
2004.
78.
“NY State Urological Society Executive Committee Meeting”, Pennsylvania Hotel,
New York, New York, June 5, 2004.
79.
“Recent Advances in the Management of Prostate Cancer”, The Pierre, New York,
New York, July 9, 2004.
59
80.
“Comprehensive Observational Multi-Center Prostate Adenocarcinoma Registry
(COMPARE), The Mandarin Oriental Hotel, Washington, D.C., July 23-25, 2004.
81.
“Current Concepts in Men’s Health 2004” The Sagamore Resort Lake George,
Bolton Landing, New York, August 13-15, 2004.
82.
“AUA Leadership Program” AUA Headquarters, Linthicum, Maryland, October 1-3,
2004.
83.
Northeastern Section of the American Urological Association Meeting, Westin
Savannah Harbor Resort, Savannah, Georgia, October 28-30, 2004.
84.
“Society of Urological Oncology Annual Meeting”, Natcher Center, National Institute
of Health Bethesda, Maryland, December 3-4, 2004.
85.
Men’s Health for the Primary Care Provider: Skills You Can Use, The Desmond
Hotel, Albany, New York, February 12, 2005.
86.
AUA Practice Management Conference, The Hotel Washington, Washington, D.C.,
February, 2005.
87.
AUA National Advocacy Conference, The Hotel Washington, Washington, D.C.,
February 28 and March 1, 2005.
88.
Levitra Faculty Update, Westin LaCantera Hotel, San Antonio, Texas, May 20-21,
2005.
89.
American Urological Association Annual Meeting, San Antonio, Texas, May 21-25,
2005.
90.
Targeting Advanced Prostate Cancer: Today and Tomorrow, CME Faculty Training
Roundtables, Essex House, New York, New York , June 24-25, 2005.
91.
Recent Advances in the Management of Prostate Cancer, Grand Hyatt New York,
New York, New York, July 29, 2005.
92.
Current Concepts in Men’s Health 2005, The Sagamore Resort Lake George,
Bolton Landing, New York, August 12-14, 2005.
93.
AUA Coding and Reimbursement Committee Meeting, AUA Headquarters,
Linthicum, Maryland, October 29, 2005.
94.
AUA Practice Management Adhoc Committee Meeting, AUA Headquarters,
Linthicum, Maryland, November 11-12, 2005.
95.
“Society of Urological Oncology Annual Meeting”, Natcher Center, National Institute
of Health Bethesda, Maryland, December 2, 2005.
96.
Upstate New York Robotic Society Meeting, Syracuse, New York, January 21,
2006.
97.
“2006 Speakers Training for Avodart (dutasteride), Hyatt Regency Lake Las Vegas,
Las Vegas, Nevada, March 3 – 4, 2006
98.
“AUA/AACU Joint Advocacy Conference, The Renaissance Mayflower Hotel,
60
Washington, D.C.,
March 27–28, 2006
99.
American Urological Association Annual Meeting, Atlanta, GA, May 20 – 25, 2006.
100.
New York State Urological Society, Inc. Executive Committee Meeting, LaGuardia
Marriott Hotel, New York, New York, June 10, 2006.
101.
GlaxoSmithKline AVO105948 Investigators’ Meeting, Westin Buckhead Atlanta,
Atlanta, GA, June 15 – 16, 2006.
102.
“2006 Prostate Cancer Review: Redefining Disease Management.” The Westin
Southfield Detroit, Southfield, Michigan, July 28, 2006.
103.
“Current Concepts in Men’s Health 2006” The Sagamore Resort, Lake George,
Bolton Landing, New York, August 11 – 13 2006.
104.
“Northeastern Section of the American Urological Association Annual Meeting”,
Ottawa, Canada, September 7-9, 2006.
105.
“American Urological Association Coding and Reimbursement Committee Meeting”,
AUA Headquarters, Linthicum, Maryland, November 4, 2006.
106.
Marriott Hotel, New York, New York, November, 11, 2006.
107.
Commercial Advisory Board for AVODART (dutasteride), The Peabody, Orlando,
FL, November 30, 2006
108.
Expert Forum: “VTP with Tookad for the Treatment of Localized Prostate Cancer”,
Hyatt Regency Bethesda, Bethesda, MD, December 1, 2006.
109.
Society of Urologic Oncology Annual Meeting, National Cancer Institute, Bethesda,
MD, December 1&2, 2006.
110.
Sanofi-Aventis Urology Speaker Training Meeting, Manchester Grand Hyatt San
Diego, CA, January 26-27, 2007.
111.
2007 SPEAKERS TRAINING for AVODART (dutasteride), Sheraton Wild Horse
Pass, Chandler, Arizona, February 3, 2007.
112.
The Northeastern Section of the American Urological Association Board of
Directors Meeting, Ritz Carlton, Washington, DC, March 24, 2007.
113.
AVO108943 Investigator Meeting, Hilton Miami Airport, Miami, FL, April 18-19,
2007.
114.
American Urological Association Annual Meeting, Anaheim, CA May 19 - 24, 2007.
115.
American Urological Association Coding and Reimbursement Committee Meeting,
Anaheim Hilton, Anaheim, CA , May 19, 2007.
116.
Society of Urologic Oncology Annual Meeting, The Anaheim Marriott, Anaheim, CA,
May 19, 2007
117.
Directors Meeting, Rochester, NY, September 5, 2007.
61
118.
Northeastern Section of the American Urological Association Annual Meeting”,
Rochester, NY, September 6-9, 2007.
119.
Marriott Hotel, New York, New York, November, 3, 2007.
120.
American Urological Association Coding and Reimbursement Committee Meeting,
AUA Headquarters, Linthicum, MD, November 17, 2007.
121.
Sexual Medicine Society of North America 2007 Winter Scientific Meeting, Westin
Chicago River North, Chicago, IL, December 6-9, 2007.
122.
2008 CPT Editorial Panel/HCPAC Annual Meeting, Rancho Las Palmas Resort &
Spa, Rancho Mirage, CA, February 7-9, 2008.
123.
Astellas YM178 Investigator Meeting, The Fairmont Hotel, Dallas, Texas, April 4-5,
2008.
124.
American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008.
125.
American Urological Association Coding & Reimbursement Committee Meeting,
Rosen Centre, Orlando, FL, May 17, 2008
126.
American Urological Association Health Policy Council Meeting, Rosen Centre,
Orlando, FL, May 19, 2008
127.
2008 CPT Editorial Panel/HCPAC Annual Meeting, Hyatt Regency Coconut Point
Resort & Spa, Bonita Springs, FL, June 5-7, 2008.
128.
Marriott Hotel, New York, New York, July 12, 2008.
129.
Bolton Landing, New York, August 8 – 10, 2008.
130.
Hyatt Regency Tamaya Resort & Spa, Santa Ana Pueblo, NM, September 18 – 20,
2008.
131.
AMA / Specialty Society RVS Update Committee Meeting, Renaissance Hotel,
Chicago, IL, October 2 & 3, 2008.
132.
2008 CPT Editorial Panel/HCPAC Annual Meeting, Sheraton Chicago Hotel &
Towers, Chicago, IL, October 23-25, 2008.
133.
AUA Headquarters, Linthicum, MD, November 15, 2008.
134.
American Urological Association Health Policy Council Fall Meeting, AUA
Headquarters, Linthicum, MD, November, 15, 2008.
135.
2009 CPT Editorial Panel/HCPAC Annual Meeting, The Wigwam Golf Resort & Spa,
Litchfield Park, Arizona, February 5-7, 2009.
136.
41st Annual Duke Urologic Assembly, Four Seasons Hotel, Las Vegas, Nevada,
62
March 7-10, 2009
137.
Meeting on Stereotactic Radiosurgery with STS, ACS, AUA, AANS, & ASTRO,
Grand Hyatt, Washington, D.C., March 22, 2009.
138.
American Urological Association Annual Meeting, Chicago, IL, April 25-30, 2009.
139.
Chicago, IL, April 26, 2009
140.
American Urological Association Health Policy Council Meeting, Chicago, IL, April
27, 2009.
141.
2009 CPT Editorial Panel/HCPAC Annual Meeting, Intercontinental Chicago O’Hare
Hotel, Rosemont, IL, June 4-6, 2009.
142.
Bolton Landing, New York, August 14-16, 2009
143.
Fairmont The Queen Elizabeth Hotel, Montreal, Quebec, Canada, October 7-11,
2009.
144.
2009 CPT Editorial Panel/HCPAC Annual Meeting, Four Seasons Resort and Club,
Dallas at Las Colinas, Texas, October 15 – 17, 2009.
145.
146.
Headquarters, Linthicum, MD, November 14, 2009.
147.
Marriott Hotel, New York, New York, November 21, 2009.
148.
2010 CPT Editorial Panel/HCPAC Annual Meeting, Hilton Bonnet Creek, Orlando,
FL, February 11 & 12, 2010.
149.
Aetna Healthcare and AUA Outreach Meeting, AUA Headquarters, Linthicum, MD,
February 22, 2010.
150.
Directors Meeting, Pittsburgh, PA, March 12-13, 2010.
151.
“AUA/AACU Joint Advocacy Conference, The Ritz-Carlton, Washington, D.C.,
March 21-23, 2010
152.
42nd Annual Duke Urologic Assembly, Disney’s Grand Floridian Resort & Spa, Lake
Buena Vista, Florida, March 25-28, 2010.
153.
UnitedHealthcare and AUA Outreach Meeting, United Corporate Headquarters,
Minnetonka, MN, April 12, 2010
American Urological Association Annual Meeting, San Francisco, CA May 28 –
June 1, 2010.
154.
155.
Section Secretaries Membership Council Meeting Marriott Marquis – San
63
Francisco, CA Saturday, May 29, 2010
156.
National Renal and Prostate Robotic Symposium, Hartford Hospital, Hartford ,
Connecticut, June 25, 2010
157.
AUX-CC-803/AUX-CC-804 Peyronie’s Phase III Investigator Meeting, The Four
Seasons Hotel, Philadelphia, PA, August 5-6, 2010.
158.
Directors Meeting, Pittsburgh, PA, September 22, 2010.
159.
Northeastern Section of the American Urological Association Annual Meeting”, The
Westin Convention Center Hotel, Pittsburgh, PA, September 22-26, 2010.
160.
161.
Headquarters, Linthicum, MD, November 13, 2010
162.
New York State Urological Society Executive Committee Meeting, via telephone
conference, November 20, 2010
163.
LESS in Urology: A Comprehensive Course on Laparoendoscopic Single Site
Surgery with Robotic LESS Surgery Symposium, Dallas, Texas, December 3-4,
2010
164.
American Medical Association CPT Editorial Panel Meeting, Naples Grand Beach
Resort, Naples, FL, February 10-12, 2011
165.
AUA / AACU Urology Joint Advocacy Conference 2011, The Ritz-Carlton,
Washington, D.C., March 27-29, 2011
166.
American Medical Association CPT Editorial Panel Meeting, Hyatt Regency, San
Francisco, CA, June 2-4, 2011
167.
Current Concepts in Men’s Health, The Sagamore, Lake George, Bolton Landing,
New York, August 12-14, 2011
168.
American Medical Association CPT Editorial Panel Meeting, Chicago Downtown
Marriott, Chicago, IL, October 13 & 14, 2011
169.
Directors Meeting, Roosevelt Hotel, New Orleans, LA, October 26, 2011
170.
AUA Northeastern Section Residents Committee Meeting, Roosevelt Hotel, New
Orleans, LA, October 28, 2011.
171.
Roosevelt Hotel, New Orleans, LA, October 26-30, 2011.
172.
American Urological Association CIGNA HealthCare Outreach Meeting, CIGNA
Headquarters, Bloomfield, CT, November 10, 2011
173.
American Urological Association and WellPoint / Anthem Outreach Meeting,
64
American Urological Associaton Headquarters, Linthicum, MD, January 11, 2012
174.
Section Secretaries/Membership Council, American Urological Association
Headquarters, Linthicum, MD, January 21, 2011
175.
American Medical Association CPT Editorial Panel Meeting, Westin LaPaloma
Resort and Spa, Tucson, Arizona, February 2-4, 2012
176.
7th Annual Urology Joint Advocacy Conference, Hyatt Regency Washington on
Capitol Hill, Washington, D.C., March 4-6, 2012
65

ronald p. kaufman, jr., md, facs

Transcription

Similar documents

Health provider directory (June 2016)